JP2009286695A - Ocular fibrous neovascularization inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a chorioretinal neovascularization inhibitor, more concretely the chorioretinal neovascularization inhibitor using a substance inhibiting the production or accumulation of chondroitin sulfate proteoglycan, and a method for screening the inhibitor. <P>SOLUTION: This chorioretinal neovascularization inhibitor suitable for the treatment or prevention of the chorioretinal neovascularization disease, such as versican siRNA containing the core site sequence of versican which is one of the chondroitin sulfate proteoglycan (CSPG), a chondroitin-4-desulfatase for desulfating the sulfate group at the 4 position of the chondroitin sulfate proteoglycan, etc., is provided as an example of examining the effect of accumulation of the chondroitin sulfate proteoglycan. The method for inhibiting the chorioretinal neovascularization based on the inhibition of accumulation of the chondroitin sulfate proteoglycan (CSPG) by administering the versican siRNA, chondroitin-4-desulfatase, etc., to a subject and the method for treating or preventing the chorioretinal neovascularization diseases such as diabetic retinopathy, etc., by utilizing the above are also provided. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to CSPG's eye tissue, particularly the retina and choroid (retina choroid), which is an active substance that has the action of promoting the degradation of chondroitin sulfate proteoglycan (CSPG), the inhibitory action of CSPG synthesis, and the inhibitory action of CSPG sulfation. The present invention relates to a deposition inhibitor, an inhibitor of vascular hyperplasia / neogenesis of the retina choroid, a method for inhibiting CSPG deposition, and treatment or prevention of ocular neovascular diseases based on the method, particularly retinopathy and macular degeneration. The present invention is a network comprising, as an active ingredient, a substance having CSPG degradation promoting action, CSPG synthesis inhibiting action, CSPG sulfation inhibiting action, such as chondroitin-4-desulfating enzyme, versican antisense drug and the like as representative examples. The present invention relates to a method for treating / preventing choroidal neovascular diseases, particularly diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration.

  Retinal choroidal neovascularization in eye diseases is a serious pathological condition that reduces visual function and leads to blindness, and is often difficult to treat. Major diseases include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, and age-related macular degeneration.

  Diabetic retinopathy is one in which ischemia is caused by retinal vascular microcirculation disorder and retinal neovascularization develops. Diabetic retinopathy is currently the leading cause of adult blindness in Japan. With long-term exposure to high blood sugar, the balance between blood coagulation ability and anticoagulation ability is inclined toward the coagulation side, vascular smooth muscle contraction is likely to occur, and ischemia due to microvascular occlusion occurs. For survival, ischemic tissue creates a fibrovascular membrane on the ischemic retina and develops new blood vessels. Then, new blood vessels are formed in the vitreous from the proliferative membrane, causing vitreous hemorrhage and causing a marked decrease in visual acuity. Furthermore, secondary glaucoma develops when a new blood vessel is stretched in the corner due to ischemia around the retina, resulting in impaired absorption of aqueous humor. Laser photocoagulation and retinal vitreous surgery are currently being performed as treatments to reduce ischemia and suppress neovascular growth, but there are many cases that lead to blindness.

  Retinal vein occlusion is mainly caused by hypertension and hyperlipidemia, and stenosis occurs in arteriovenous intersection veins due to arteriosclerosis, etc., and microembolic substances deposit in the stenotic blood vessels, resulting in further stenosis and occlusion It is a disease state. The ocular vasculature forms the final artery, and blood flows to the peripheral blood vessels at the arterial branch and returns to the veins as blood reflux from the peripheral blood vessels. When the retinal vena cava is blocked, blood that has flowed to the periphery at a relatively high pressure is blocked by the blocked vein, resulting in retinal hemorrhage and vitreous hemorrhage as a morphological breakdown of the vein, resulting in significant visual loss. cause. The retinal tissue in the dominant region of the vein becomes ischemic due to the disruption of blood flow, and a new blood vessel is generated. Secondary glaucoma and vitreous hemorrhage are complicated by the same mechanism as diabetic retinopathy. Sometimes retinal detachment and macular edema due to vascular disruption of the retinal macular region have also caused disability leading to blindness. Treatment is laser photocoagulation. Vitreoretinopathy is performed for recurrent vitreous hemorrhage.

  Retinopathy of prematurity is a disease in which neovascularization develops due to abrupt relative ischemia of immature tissue, and complications include vitreous hemorrhage and traction retinal detachment. Born as a premature baby and exposed to high concentrations of oxygen in an incubator for a period of time to survive. The growth of retinal blood vessels in premature babies is also inadequate, and the retinal blood vessels do not reach the surrounding retinal tissues sufficiently. Under high-concentration oxygen, immature retinal blood vessel growth is unnecessary, so blood vessel growth stops, and management under an incubator is no longer necessary, and the air is returned to a relatively low oxygen concentration atmosphere. When this occurs, new blood vessels develop due to relative ischemia, causing significant visual impairment. Treatment may include laser photocoagulation and retinal hyaline surgery. The visual prognosis is very poor.

  Age-related macular degeneration, in which new blood vessels develop from the choroid under the retina of an unexplained retinal macular region, causing damage to the retinal tissue, is also an eye disease that leads to blindness. In age-related macular degeneration, choroidal neovascularization in the macular region occurs and proliferates, and neovascularization proliferates under the retina, retinal tissue, and in front of the retina, resulting in marked visual loss due to macular edema and destruction. It is the first place in the middle of blindness. If treatment is away from the foveal fovea, laser photocoagulation is performed. Recently, photodynamic therapy has been tried for lesions in the fovea, and surgical treatment has also been performed, but no solid treatment has been developed.

  As a method for treating ocular diseases caused by retina choroidal neovascularization, surgical treatment such as surgery and laser photocoagulation has been mainly performed, but development of drug therapy has just started. Currently, vascular endothelial growth factor (VEGF) is attracting attention as a factor that promotes retina choroidal neovascularization, and the development of drugs that inhibit the action of VEGF is considered to be the best method at present. (Non-Patent Document 1). Therefore, research and development of new therapeutic agents targeting VEGF have recently been promoted (Non-patent Document 2). However, since VEGF also acts on VEGF receptors that are constitutively expressed in vascular endothelial cells throughout the body, it is urgent to develop therapeutic agents that act more specifically in pathological conditions.

  On the other hand, the proteoglycan that is a target substance of the present invention is a generic term for molecules having a structure in which one or more glycosaminoglycan (GAG) chains are covalently bound to a protein called a core protein, and is a cell surface or extracellular matrix. It is a constituent component (Non-Patent Documents 3 and 4). The specific sugar chain structure of the GAG chain bound to proteoglycan is thought to be responsible for the various functions of proteoglycan. Ketalan sulfate sulfate proteoglycan is roughly divided into four. (Non-patent documents 5 to 11)

  On the other hand, chondroitin sulfate proteoglycan is an essential molecule in the embryonic period and is abundant in each organ, but it is known that it decreases with birth, growth and aging. Not yet clear. In recent years, it has been found that mice genetically deficient in CSPG fall into embryonic lethality and organ dysplasia, and thus recognition of CSPG as an indispensable molecule in the living body has increased.

  In the retina choroid, CSPG is distributed in the optic nerve fiber layer and the photoreceptor intermediate layer, and is considered to play a role of supporting nerves and pigment epithelial cells (Non-patent Document 12). However, there are no previous reports that have clarified how CSPG is associated with retina choroidal neovascularization, and no studies have been targeted.

  This time, CSPG as a therapeutic target, different approaches, such as chondroitin-4-desulfating enzyme that desulfates the 4-position sulfate group, and gene silencing (RNA interference: RNAi) of versican which is one of CSPG And verified the in vivo effect. As with the chondroitinase ABC described above, there has been no report that RNAi is used to suppress the expression of C6ST and GalNAc and control the dynamics of CSPG in vivo.

Witmer AN, Vrensen GFJM, Van Noorden CJF and Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye diseases.Prog Retin Eye Res. 2003 Jan; 22 (1): 1-29. Review. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. Jun; 9 (6): 669-79. Review. Berfield M: Annu Rev Biochem 1999 68: 729-777 Iozzo RV: Annu Rev Biochem 1998 67: 609-652 Lindahl, U et al. (1972) In Glycoproteins (Gottschalk, A. ed) pp. 491-517, Elsevier, New York. Oegema, T et al. J. Biol. Chem. (1984) 259, 1720-1726 Sugahara, K et al. J. Biol. Chem. (1988) 263, 10168-10174 Sugahara, K et al. J. Biol. Chem. (1992) 267, 6027-6035 De Waard et al. J. Biol. Chem. (1992) 267, 6036-6043 Moses, J, Oldberg et al. Eur. J. Biol. (1992) 248, 521-526 Yamada, S et al. Trends in Glycoscience and Glycotechnology,. (1998) 10, 95-123 Inatani M et al. Prog Retin Eye Res. 21: 429-447,2002

  An object of the present invention is to provide a retina-choroidal neovascularization inhibitor, a therapeutic agent for a retina-choroidal neovascularization disease containing the drug as an active ingredient, and a screening method for a retina-choroidal neovascularization inhibitor.

  As the inventors of the present invention have conducted extensive research to develop such drugs, excessive accumulation of CSPG, which has not previously been considered as the etiology of angiogenesis lesions of the retina choroid, is caused by proliferation of vascular endothelial cells of the retina choroid. In addition, we thought that it may contribute to angiogenic lesions. Based on this idea, the present inventors have conducted research using a plurality of different approaches, and as a result, have demonstrated that retinal choroidal neovascularization can be suppressed by inhibiting the accumulation or biosynthesis of chondroitin sulfate proteoglycans. The present invention has been completed.

The present invention relates to a retina choroidal neovascularization inhibitor, a therapeutic agent for a retina choroidal neovascularization disease containing the drug as an active ingredient, a screening method for a retina choroidal neovascularization inhibitor, and more specifically,
[1] A retina choroidal neovascularization inhibitor comprising, as an active ingredient, a substance that inhibits the production or accumulation of chondroitin sulfate proteoglycan,
[2] The drug according to [1], wherein the substance is a substance having a chondroitin sulfate proteoglycan degradation promoting action,
[3] The drug according to [1], wherein the substance has a chondroitin sulfate proteoglycan synthesis inhibitory action,
[4] The drug according to [1], wherein the substance is a substance having a chondroitin sulfate proteoglycan desulfation effect,
[5] The drug according to [1], wherein the substance has a chondroitin sulfate proteoglycan sulfation inhibitory action.
[6] The drug according to any one of [1] to [5], wherein production or accumulation of chondroitin sulfate proteoglycan is inhibited in the retina choroid,
[7] The drug according to any one of [1] to [6], for treatment or prevention of retina choroidal neovascular disease,
[8] The drug according to [7], wherein the retina choroidal neovascularization disease is a retinal neovascularization disease,
[9] The drug according to [7], wherein the retina choroidal neovascularization disease is diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, or age-related macular degeneration,
[10] A screening method for a retina choroidal neovascularization inhibitor, comprising selecting a substance having an action of inhibiting the production or accumulation of chondroitin sulfate proteoglycan from a test sample,
[11] The screening method according to [10], including a step of selecting a substance having the action according to any one of (a) to (d) below:
(A) Degradation promoting action of chondroitin sulfate proteoglycan (b) Synthesis inhibitory action of chondroitin sulfate proteoglycan (c) Desulfation action of chondroitin sulfate proteoglycan (d) Suppression action of chondroitin sulfate proteoglycan [12] Inhibition of choroidal angiogenesis [12] The screening method according to [10] or [11], wherein the agent is used for treatment or prevention of a choroidal neovascularization disease,
Is provided.
The present invention further relates to the following.
[13] Use of the drug according to any one of [1] to [9] in the manufacture of a retina choroidal neovascularization inhibitor,
[14] A method for treating a choroidal neovascularization disease, comprising a step of administering the drug according to any one of [1] to [9] to an individual (patient or the like),
[15] A composition comprising the drug according to any one of [1] to [9] and a pharmaceutically acceptable carrier.

  An object of the present invention is to suppress the deposition of CSPG (chondroitin sulfate proteoglycan) on the choroidal tissue, and to promote the degradation of CSPG, the inhibitory action of CSPG synthesis, the inhibitory action of CSPG sulfation, and the mechanism of retina choroidal neovascularization One object is to provide a method for treating or preventing a disease.

  According to the present invention, it has been revealed that chondroitin sulfate proteoglycan generation and accumulation are related to the onset of retina choroidal neovascularization. Inhibition of chondroitin sulfate proteoglycan production and accumulation has been shown to suppress choroidal neovascularization. It will be possible to provide a therapeutic agent for a recurrent choroidal neovascularization disease that has never been seen before. In particular, retina choroidal neovascularization is closely related to diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration, etc. Drugs have important medical and industrial significance.

Hereinafter, the present invention will be described in detail.
As a pathological condition associated with diabetic retinopathy, which is one of the typical retina choroidal neovascular diseases, there is retinal neovascularization that develops due to ischemia due to microcirculatory disturbance of retinal blood vessels. The present inventors paid attention to the function of chondroitin sulfate proteoglycan in order to suppress the angiogenic state in the retinal tissue of the eye as one effective method for treating diabetic retinopathy. A state of suppressing chondroitin sulfate proteoglycan accumulation in a diabetic retinopathy mouse model was analyzed and analyzed in detail. As a result, the accumulation of chondroitin sulfate proteoglycan was improved as compared to wild-type retinal tissue, and angiogenesis was achieved. Etc. were suppressed. That is, it has been found that inhibition of chondroitin sulfate proteoglycan generation or accumulation promotes improvement of abnormal accumulation state of chondroitin sulfate proteoglycan in retinal tissues that are deeply involved in diabetic retinopathy, leading to suppression of choroidal neovascularization. It was.

  The present invention relates to a retina choroidal neovascularization inhibitor comprising, as an active ingredient, a substance that inhibits the production or accumulation of chondroitin sulfate proteoglycans.

  The “chondroitin sulfate proteoglycan” of the present invention is one of proteoglycans and is a generic name for a covalently bonded compound of chondroitin sulfate / dermatan sulfate, which is a typical sulfated mucopolysaccharide, and a protein (core protein). The “chondroitin sulfate proteoglycan” in the present invention is preferably a human chondroitin sulfate proteoglycan, but the species from which the chondroitin sulfate proteoglycan is derived is not particularly limited, and is a protein equivalent to a chondroitin sulfate proteoglycan in a non-human organism (such as a homolog or ortholog). ) Is also included in the “chondroitin sulfate proteoglycan” in the present invention. For example, the present invention can be carried out if the organism has a protein corresponding to human chondroitin sulfate proteoglycan and has a protein equivalent to human chondroitin sulfate proteoglycan. The chondroitin sulfate proteoglycan in the present invention includes a so-called part-time proteoglycan in which a glycosaminoglycan (GAG) chain is temporarily bound due to inflammation or the like to become a proteoglycan.

  In the following description, examples of chondroitin sulfate proteoglycans include aggrican, versican, neurocan, brevican, βglycan, Decorin, Biglycan, Fibromodulin, and PG-Lb. The chondroitin sulfate proteoglycan in the present invention is not limited to these, and any substance having activity as a chondroitin sulfate proteoglycan may be used. Here, the activity of chondroitin sulfate proteoglycan includes, for example, cell adhesion ability or cell growth promotion. A person skilled in the art can evaluate the activity as a chondroitin sulfate proteoglycan by the following method. Protein containing a partial region of chondroitin sulfate proteoglycan amino acid sequence, or high homology with a partial region (usually 70% or more, preferably 80% or more, more preferably 90% or more, most preferably 95% or more) Measure proliferation of tumor cells (eg, Caco-2, HT-29 cells, etc.) in the presence of proteins with A protein having an effect of promoting mitotic proliferation can be determined as a protein having chondroitin sulfate proteoglycan activity (Int J Exp Pathol. 2005 Aug; 86 (4): 219-29 and Histochem Cell Biol. 2005 Aug; 124 (2): 139-49). Here, high homology means 50% or more, preferably 70% or more, more preferably 80% or more, more preferably 90% or more (for example, 95% or more, further 96%, 97%, 98% or 99%). % Or higher) homology. This homology is determined by the mBLAST algorithm (Altschul et al. (1990) Proc. Natl. Acad. Sci. USA 87: 2264-8; Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-7 ) Can be determined.

  In the present invention, “retinochoroidal neovascularization” refers to a state in which angiogenesis has occurred in the retina choroid, and includes angiogenesis marker expression such as an increase in CD31-positive cells and retinal collagen growth. Including.

  Examples of `` inhibiting production or accumulation '' of chondroitin sulfate proteoglycans in the present invention include `` promotion of degradation '', `` synthesis inhibition '', `` desulfation '', `` sulfation inhibition '' and the like of chondroitin sulfate proteoglycans, However, the present invention is not limited to this, and it means that the abundance, function or activity of chondroitin sulfate proteoglycan is reduced or eliminated as compared with the comparison target. In the present invention, the `` substance that inhibits production or accumulation '' of chondroitin sulfate proteoglycan is not particularly limited, but preferably `` substance that has an action of promoting degradation of chondroitin sulfate proteoglycan '', `` substance that has an inhibitory effect on synthesis '', `` “Substance having desulfation action” or “substance having sulfation inhibitory action”.

  The “promotion of degradation” of chondroitin sulfate proteoglycan includes, for example, inhibition of expression / decrease in the expression of a protein that is the core of chondroitin sulfate proteoglycan. Here, the “protein which becomes the core of chondroitin sulfate proteoglycan” includes, for example, core proteins such as aggrican, versican, neurocan, brevican and the like if they are matrix type chondroitin sulfate proteoglycans. Examples of membrane-type chondroitin sulfate proteoglycans include core proteins such as βglycan, Decorin, Biglycan, Fibromodulin, and PG-Lb. These are only examples, and are not limited to these, and may be any protein that can be a core of chondroitin sulfate proteoglycans.

  “Expression” includes “transcription” from a gene or “translation” into a polypeptide and “degradation inhibition” of a protein. “Expression of the protein that is the core of chondroitin sulfate proteoglycan” means that transcription and translation of the gene encoding the protein that is the core of chondroitin sulfate proteoglycan occurs, or the protein that is the core of chondroitin sulfate proteoglycan by these transcription and translation Is generated. Examples of the “function of the protein serving as the core of chondroitin sulfate proteoglycan” include, for example, the function of the protein binding to chondroitin sulfate and the binding to other components in the cell. The various functions described above can be appropriately evaluated (measured) by those skilled in the art using general techniques. Specifically, the method described in the examples described later, or the method can be appropriately modified and carried out.

  Furthermore, “promotion of degradation” of chondroitin sulfate proteoglycan may be an increase in expression of an enzyme that cleaves or degrades chondroitin sulfate proteoglycan or an enzyme related thereto. Examples of these enzymes include, but are not limited to, metalloproteinases (eg, ADAMTS-1, ADAMTS-4, ADAMTS-5, etc.), chondroitinase (chondroitinase), and Calpain I. “Acceleration of degradation” may be a decrease in the abundance of chondroitin sulfate proteoglycan caused by administration of these enzymes or a part of the enzymes.

  “Degradation promotion” may be caused by administration of a substance that promotes suppression of chondroitin sulfate proteoglycan expression. Examples of these substances include, but are not limited to, n-butylate, Diethylcarbamazepine, Tunicamycin, non-steroidal estrogen, and Cyclofenil deiphenol.

Preferable embodiments of the “substance having a decomposition promoting action” include, for example, compounds (nucleic acids) selected from the group consisting of the following (a) to (c).
(A) An antisense nucleic acid for a transcription product of a gene encoding a core protein of chondroitin sulfate proteoglycan or a part thereof (b) A ribozyme activity that specifically cleaves a transcription product of a gene encoding the core protein of chondroitin sulfate proteoglycan Nucleic acid (c) Nucleic acid having an action of inhibiting the expression of the gene encoding the core protein of chondroitin sulfate proteoglycan by RNAi effect

Examples of the “substance having a decomposition promoting action” include compounds selected from the group consisting of the following (a) to (c).
(A) an antibody that binds to the core protein of chondroitin sulfate proteoglycan (b) a chondroitin sulfate proteoglycan variant having a dominant negative property to the core protein of chondroitin sulfate proteoglycan (c) a small molecule that binds to the core protein of chondroitin sulfate proteoglycan Compound

  “Synthetic inhibition” of chondroitin sulfate proteoglycan includes, for example, inhibition of glycosaminoglycan biosynthesis, inhibition of enzymes involved in chondroitin sulfate proteoglycan synthesis, but is not limited thereto, and chondroitin sulfate proteoglycan is synthesized. Refers to inhibiting any of the processes.

  As substances that inhibit the synthesis of chondroitin sulfate proteoglycans, examples of substances that inhibit the biosynthesis of glycosaminoglycans include β-D-xyloside, 2-deoxy-D-glucose (2-DG), ethane-1- Examples include hydroxy-1,1-diphosphonate (ETDP) and 5-hexyl-2-deoxyuridine (HUdR). These and other substances inhibit the biosynthesis of glycosaminoglycans and inhibit the synthesis of chondroitin sulfate proteoglycans.

  On the other hand, examples of enzymes involved in chondroitin synthesis include GalNAc4ST-1, GalNAc4ST-2, GALNAC4S-6ST, UA2OST, GalT-I, GalT-II, GlcAT-I, and XylosylT. By inhibiting these and other enzymes and suppressing their expression, the synthesis of chondroitin sulfate proteoglycans is inhibited.

Preferable embodiments of the “substance having a synthesis inhibitory action” include, for example, compounds (nucleic acids) selected from the group consisting of the following (a) to (c).
(A) an antisense nucleic acid for a transcription product of a gene encoding chondroitin sulfate proteoglycan synthase or a part thereof (b) a nucleic acid having a ribozyme activity that specifically cleaves a transcription product of a gene encoding chondroitin sulfate proteoglycan synthase ( c) Nucleic acid having an action of inhibiting the expression of a gene encoding chondroitin sulfate proteoglycan synthase by RNAi effect

Examples of the “substance having a synthetic inhibitory action” include compounds selected from the group consisting of the following (a) to (c).
(A) an antibody that binds to chondroitin sulfate proteoglycan synthase (b) a chondroitin sulfate proteoglycan synthase variant having a dominant negative property with respect to chondroitin sulfate proteoglycan synthase (c) a low molecular compound that binds to chondroitin sulfate proteoglycan synthase

  “Desulfation” of chondroitin sulfate proteoglycans refers to removal of sulfate groups in chondroitin sulfate proteoglycans, such as desulfation by endogenous or externally administered desulfating enzymes, or sulfate by a compound that suppresses sulfation. Examples include, but are not limited to, the process of removing sulfate groups.

  Examples of desulfating enzymes include Chondroitin-4-sulfatase and Chondroitin-6-sulfatase. Examples of compounds that suppress sulfation include Chlorate and EGF receptor antagonist.

Preferable embodiments of the “substance having desulfating action” include, for example, compounds (nucleic acids) selected from the group consisting of the following (a) to (c).
(A) an antisense nucleic acid for a transcription product of a gene encoding a chondroitin sulfate proteoglycan desulfase inhibitor protein or a part thereof (b) a transcript of a gene encoding a chondroitin sulfate proteoglycan desulfase inhibitor protein is specifically cleaved Nucleic acid having ribozyme activity (c) Nucleic acid having an action of inhibiting the expression of a gene encoding a chondroitin sulfate proteoglycan desulfase inhibitor protein by the RNAi effect

Examples of the “substance having desulfating action” include compounds selected from the group consisting of the following (a) to (c).
(A) an antibody that binds to a chondroitin sulfate proteoglycan desulfase inhibitor compound (b) a chondroitin sulfate proteoglycan desulfation inhibitor protein variant that has dominant negative properties against the chondroitin sulfate proteoglycan desulfase inhibitor protein (c) chondroitin sulfate Low molecular weight compounds that bind to proteoglycan desulfase inhibitor compounds

  Here, the “desulfation-inhibiting compound” is not limited to proteins, and includes non-protein compounds such as coenzymes, for example.

  The “sulfation inhibitory action” of chondroitin sulfate proteoglycan includes, for example, inhibition of sulfate group transferase, but is not limited thereto, and refers to inhibition of sulfation that occurs during the synthesis of chondroitin sulfate proteoglycan. .

  Examples of the sulfotransferase include C4ST-1 (Chondroitin DN-acetylgalactosamine-4-O-sulfotransferase 1), C4ST-2 (Chondroitin DN-acetylgalactosamine-4-O-sulfotransferase 2), C4ST-3 (Chondroitin DN- Examples thereof include acetylgalactosamine-4-O-sulfotransferase 3), D4ST, C6ST-1, and C6ST-2.

Preferable embodiments of “substances having a sulfation inhibiting action” include, for example, compounds (nucleic acids) selected from the group consisting of the following (a) to (c).
(A) An antisense nucleic acid for a transcript of a gene encoding chondroitin sulfate proteoglycan sulfate transferase or a part thereof (b) A ribozyme activity that specifically cleaves a transcript of a gene encoding chondroitin sulfate proteoglycan sulfate transferase (C) a nucleic acid having an action of inhibiting the expression of a gene encoding chondroitin sulfate proteoglycan sulfate transferase by the RNAi effect

Examples of the “substance having sulfation inhibitory action” include compounds selected from the group consisting of the following (a) to (c).
(A) an antibody that binds to chondroitin sulfate proteoglycan sulfate group (b) a chondroitin sulfate proteoglycan sulfate group variant (c) a low molecular weight compound that binds to chondroitin sulfate proteoglycan sulfate group

  The enzymes exemplified above include not only one enzyme corresponding to one gene but also an enzyme group sharing certain characteristics. For example, chondroitinase is a generic term for enzymes such as ABC, AC, and B that share the characteristics of mucopolysaccharide-degrading enzymes but differ in substrate specificity. For example, chondroitinase AC I cleaves the N-acetylhexosaminide bond of chondroitin sulfates (A, C or E), chondroitin, chondroitin sulfate-dermatan sulfate hybrid type and hyaluronic acid. An oligosaccharide having a Δ4-glucuronic acid residue at the non-reducing end is generated. This enzyme does not act on dermatan sulfate (chondroitin sulfate B, having hexuronic acid L-iduronic acid), ketalan sulfate, heparan sulfate, and heparin. In addition, chondroitinase AC II cleaves the N-acetylhexosaminide bond of chondroitin, chondroitin sulfate A and chondroitin sulfate C in a desorption reaction, and produces Δ4-unsaturated disaccharides (ΔDi-0S, ΔDi- 4S and ΔDi-6S). This enzyme also works well on hyaluronic acid. It does not act on dermatan sulfate (chondroitin sulfate B) and becomes a competitive inhibitor of this enzyme. Chondroitinase B (dermatanase) is an oligosaccharide having a Δ4-hexuronic acid residue at the non-reducing end by cleaving the N-acetylgalactosaminide bond bound to L-iduronic acid of dermatan sulfate by elimination reaction. Disaccharide and tetrasaccharide). This enzyme does not act on chondroitin sulfate A and chondroitin sulfate C that do not contain L-iduronic acid. Dermatan, a derivative obtained by removing the sulfate group of dermatan sulfate, does not serve as a substrate for this enzyme. The site where the second position of the L-iduronic acid unit of dermatan sulfate is sulfated is better cleaved by this enzyme. Chondroitinase ABC cleaves the N-acetylhexosaminide bond of chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, chondroitin and hyaluronic acid in a reactive manner, resulting in a Δ4-hexuronic acid residue at the non-reducing end Mainly produces disaccharides with This enzyme does not act on ketalan sulfate, heparin and heparan sulfate. Chondroitinase is a generic name for such enzymes that have different properties but have a common property called mucopolysaccharide-degrading enzyme. Chondroitinase ACI, Chondroitinase AC II, Chondrotinase B, and Chondrotinase ABC exemplified here Not limited.

  Moreover, the enzyme group which shares such a characteristic does not necessarily correspond to one gene on genomic DNA. For example, chondroitin-4-sulfatase and chondroitin-6-sulfatase are sequences referred to by a plurality of accession numbers on the genome database (for example, Genbank accession number NT_039500 (part of which is accession number CAAA01098429 (SEQ ID NO: 73)), and NT_078575, NT_039353, NW_001030904, NW_001030811, NW_001030796, NW_000349) are searched on the public gene database Genbank.

Among those exemplified above, those corresponding to individual genes are shown as follows. That is, examples of the above-mentioned chondroitin sulfate proteoglycans include aggrican, versican (versican), neurocan, brevican, βglycan, Decorin, Biglycan, Fibromodulin, PG-Lb, enzymes that cleave or decompose chondroitin sulfate proteoglycans, and enzymes related thereto. Illustrated, ADAMTS-1, ADAMTS-4, ADAMTS-5, Calpain I, exemplified as enzymes involved in chondroitin synthesis, GalNAc4ST-1, GalNAc4ST-2, GALNAC4S-6ST, UA2OST, GalT-I, GalT-II, GlcAT -I, XylosylT, the accession number in the public gene database Genbank of the genes that encode C4ST-1, C4ST-2, C4ST-3, D4ST, C6ST-1 and C6ST-2 in humans, exemplified as sulfate group transferase The nucleotide sequence and amino acid sequence are as follows.
aggrican (accession number NM_007424, nucleotide sequence SEQ ID NO: 1, amino acid sequence SEQ ID NO: 2)
versican (accession number BC096495, nucleotide sequence SEQ ID NO: 3, amino acid sequence SEQ ID NO: 4)
neurocan (accession number NM_010875, nucleotide sequence SEQ ID NO: 5, amino acid sequence SEQ ID NO: 6)
brevican (accession number NM_007529, base sequence SEQ ID NO: 7, amino acid sequence SEQ ID NO: 8)
βglycan (accession number AF039601, nucleotide sequence SEQ ID NO: 9, amino acid sequence SEQ ID NO: 10)
Decorin (Accession number NM_007833, nucleotide sequence SEQ ID NO: 11, amino acid sequence SEQ ID NO: 12)
Biglycan (Accession number BC057185, base sequence SEQ ID NO: 13; amino acid sequence SEQ ID NO: 14)
Fibromodulin (accession number NM_021355, nucleotide sequence SEQ ID NO: 15 and amino acid sequence SEQ ID NO: 16)
PG-Lb (accession number NM_007884, base sequence SEQ ID NO: 17, amino acid sequence SEQ ID NO: 18)
ADAMTS-1 (accession number NM_009621, base sequence SEQ ID NO: 19 and amino acid sequence SEQ ID NO: 20)
ADAMTS-4 (Accession number NM_172845, SEQ ID NO: 21 of nucleotide sequence, SEQ ID NO: 22 of amino acid sequence)
ADAMTS-5 (Accession number AF140673, nucleotide sequence SEQ ID NO: 23, amino acid sequence SEQ ID NO: 24)
Calpain I (accession number NM_007600, nucleotide sequence SEQ ID NO: 25, amino acid sequence SEQ ID NO: 26)
GalNAc4ST-1 (accession number NM_175140, nucleotide sequence SEQ ID NO: 27, amino acid sequence SEQ ID NO: 28)
GalNAc4ST-2 (accession number NM_199055, nucleotide sequence SEQ ID NO: 29, amino acid sequence SEQ ID NO: 30)
GALNAC4S-6ST (accession number NM_029935, base sequence SEQ ID NO: 31, amino acid sequence SEQ ID NO: 32)
UA2OST (accession number NM_177387, base sequence SEQ ID NO: 33, amino acid sequence SEQ ID NO: 34)
GalT-I (accession number NM_016769, base sequence SEQ ID NO: 35, amino acid sequence SEQ ID NO: 36)
GalT-II (accession number BC064767, base sequence SEQ ID NO: 37, amino acid sequence SEQ ID NO: 38)
GlcAT-I (accession number BC058082, base sequence SEQ ID NO: 39, amino acid sequence SEQ ID NO: 40, or accession number NM_024256, base sequence SEQ ID NO: 41, amino acid sequence SEQ ID NO: 42)
XylosylT (accession number NM_145828, nucleotide sequence SEQ ID NO: 43, amino acid sequence SEQ ID NO: 44)
C4ST-1 (Accession number NM_021439, nucleotide sequence SEQ ID NO: 45, amino acid sequence SEQ ID NO: 46)
C4ST-2 (Accession number NM_021528, nucleotide sequence SEQ ID NO: 47, amino acid sequence SEQ ID NO: 48)
C4ST-3 (accession number XM_355798, base sequence SEQ ID NO: 49, amino acid sequence SEQ ID NO: 50)
D4ST (accession number NM_028117, nucleotide sequence SEQ ID NO: 51, amino acid sequence SEQ ID NO: 52)
C6ST-1 (Accession number NM_016803, nucleotide sequence SEQ ID NO: 53, amino acid sequence SEQ ID NO: 54)
C6ST-2 (accession number AB046929, nucleotide sequence SEQ ID NO: 55, amino acid sequence SEQ ID NO: 56)

  Even proteins other than the above have high homology (usually 70% or more, preferably 80% or more, more preferably 90% or more, most preferably 95% or more) with the sequences described in the sequence listing, for example. And the protein which has the function (For example, the function etc. which couple | bond with the structural component in a cell) which the said protein has is contained in the said protein of this invention. The protein is, for example, SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, A protein consisting of an amino acid sequence according to any one of 42, 44, 46, 48, 50, 52, 54, and 56, wherein one or more amino acids are added, deleted, substituted, or inserted, and The number of amino acids to be changed is within 30 amino acids, preferably within 10 amino acids, more preferably within 5 amino acids, and most preferably within 3 amino acids.

  Examples of the gene in the present invention include SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37. , 39, 41, 43, 45, 47, 49, 51, 53, 55, an endogenous gene (such as a homolog of the above-mentioned human gene) in another organism corresponding to the DNA comprising the base sequence described in any one of included.

  SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 , 47, 49, 51, 53, and 55, the endogenous DNA of other organisms corresponding to the DNA consisting of the base sequence described in any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55 It has high homology with the DNA described in 1. High homology means 50% or more, preferably 70% or more, more preferably 80% or more, more preferably 90% or more (for example, 95% or more, or 96%, 97%, 98% or 99% or more). ) Homology. This homology is determined by the mBLAST algorithm (Altschul et al. (1990) Proc. Natl. Acad. Sci. USA 87: 2264-8; Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-7 ) Can be determined. When the DNA is isolated from a living body, SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, and 55 are considered to hybridize under stringent conditions. Here, as “stringent conditions”, for example, “2 × SSC, 0.1% SDS, 50 ° C.”, “2 × SSC, 0.1% SDS, 42 ° C.”, “1 × SSC, 0.1% SDS, 37 ° C.” More stringent conditions include “2 × SSC, 0.1% SDS, 65 ° C.”, “0.5 × SSC, 0.1% SDS, 42 ° C.” and “0.2 × SSC, 0.1% SDS, 65 ° C.” Can do.

  A person skilled in the art is able to measure a protein functionally equivalent to the above protein from the above highly homologous proteins by measuring the activity of the chondroitin sulfate proteoglycan degradation promoting action, synthesis inhibiting action, desulfating action or sulfation inhibiting action. Can be obtained as appropriate. A specific activity measurement method is described in the section of the screening method in the present invention described later. Further, those skilled in the art can appropriately obtain an endogenous gene corresponding to the above gene in another organism based on the base sequence of the above gene. In the present specification, the protein and gene corresponding to the protein and gene in organisms other than humans, or the protein and gene functionally equivalent to the protein and gene described above are also simply described with the above names. There is a case.

  The protein of the present invention can be prepared not only as a natural protein but also as a recombinant protein using a gene recombination technique. The natural protein can be prepared, for example, by a method using affinity chromatography using an antibody against the protein against an extract of a cell (tissue) considered to express the protein. On the other hand, the recombinant protein can be prepared, for example, by culturing cells transformed with DNA encoding the protein. The above protein of the present invention is suitably used, for example, in the screening method described below.

  The “nucleic acid” in the present invention means RNA or DNA. Chemically synthesized nucleic acid analogs such as so-called PNA (peptide nucleic acid) are also included in the nucleic acid of the present invention. PNA is obtained by replacing the pentose / phosphate skeleton, which is the basic skeleton structure of nucleic acids, with a polyamide skeleton having glycine as a unit, and has a three-dimensional structure very similar to nucleic acids.

  As a method for inhibiting the expression of a specific endogenous gene, a method using an antisense technique is well known to those skilled in the art. There are several factors as described below for the action of the antisense nucleic acid to inhibit the expression of the target gene. Inhibition of transcription initiation by triplex formation, inhibition of transcription by hybridization with a site where an open loop structure was locally created by RNA polymerase, inhibition of transcription by hybridization with RNA undergoing synthesis, intron and exon Splicing inhibition by hybridization at splice point, splicing inhibition by hybridization with spliceosome formation site, inhibition of translocation from nucleus to cytoplasm by hybridization with mRNA, hybridization with capping site and poly (A) addition site Inhibition of splicing by RNA, inhibition of translation initiation by hybridization with a translation initiation factor binding site, translation inhibition by hybridization with a ribosome binding site near the initiation codon, peptide by hybridization with an mRNA translation region or polysome binding site Elongation inhibition, and the like inhibiting gene expression by hybrid formation with the site of interaction between nucleic acids and proteins. In this way, antisense nucleic acids inhibit the expression of target genes by inhibiting various processes such as transcription, splicing or translation (Hirashima and Inoue, Shinsei Kagaku Kenkyu 2 Lecture and Expression of Nucleic Acid IV Gene, Japan Biochemical) (Academic Society, Tokyo Chemical Doujin, 1993, 319-347).

  The antisense nucleic acid used in the present invention is capable of expressing a gene encoding any one of the above-mentioned chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, and sulfotransferase, and / or Or you may inhibit a function. As one embodiment, antisense complementary to the untranslated region near the 5 ′ end of mRNA of the gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, or sulfotransferase described above If the sequence is designed, it is considered effective for inhibiting translation of the gene. In addition, a sequence complementary to the coding region or the 3 ′ untranslated region can also be used. Thus, the nucleic acid containing the above-mentioned chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, or the translation region of the gene encoding the sulfotransferase, and the antisense sequence of the sequence of the untranslated region Are also included in the antisense nucleic acid utilized in the present invention. The antisense nucleic acid to be used is linked downstream of an appropriate promoter, and preferably a sequence containing a transcription termination signal is linked on the 3 ′ side. The nucleic acid thus prepared can be transformed into a desired animal (cell) using a known method. The sequence of the antisense nucleic acid is a gene encoding a core protein, a synthetic enzyme, a desulfating enzyme inhibitory protein, or a sulfotransferase, or a part thereof, which is contained in an endogenous chondroitin sulfate proteoglycan possessed by an animal (cell) to be transformed. Although it is preferably a complementary sequence, it may not be completely complementary as long as gene expression can be effectively suppressed. The transcribed RNA preferably has a complementarity of 90% or more, most preferably 95% or more, to the transcript of the target gene. In order to effectively inhibit the expression of a target gene using an antisense nucleic acid, the length of the antisense nucleic acid is preferably at least 15 bases and less than 25 bases, but the antisense nucleic acid of the present invention is not necessarily of this length. For example, it may be 100 bases or more, or 500 bases or more.

  Although the antisense nucleic acid of the present invention is not particularly limited, for example, the base sequence of the Versican gene (GenBank accession number BC096495, SEQ ID NO: 3), C4ST-1 (GenBank accession number NM_021439, SEQ ID NO: 45) ), C4ST-2 (GenBank accession number NM — 021528, SEQ ID NO: 47), C4ST-3 (GenBank accession number XM — 355798, SEQ ID NO: 49), and the like.

  Inhibition of the expression of the above chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, or sulfate-encoding gene can also be carried out using ribozyme or ribozyme-encoding DNA. is there. A ribozyme refers to an RNA molecule having catalytic activity. Some ribozymes have a variety of activities, but research focusing on ribozymes as enzymes that cleave RNA has made it possible to design ribozymes that cleave RNA in a site-specific manner. Some ribozymes have a size of 400 nucleotides or more, such as group I intron type and M1 RNA contained in RNase P, but some have an active domain of about 40 nucleotides called hammerhead type or hairpin type. (Makoto Koizumi and Eiko Otsuka, Protein Nucleic Acid Enzymes, 1990, 35, 2191.)

  For example, the self-cleaving domain of the hammerhead ribozyme cleaves 3 ′ of C15 in the sequence G13U14C15, but base pairing between U14 and A9 is important for its activity, and instead of C15, A15 or U15 However, it has been shown that it can be cleaved (Koizumi, M. et al., FEBS Lett, 1988, 228, 228.). By designing a ribozyme whose substrate binding site is complementary to the RNA sequence in the vicinity of the target site, it is possible to create a restriction RNA-cleaving ribozyme that recognizes the sequence UC, UU or UA in the target RNA (Koizumi, M. et al., FEBS Lett, 1988, 239, 285., Makoto Koizumi and Eiko Otsuka, Protein Nucleic Acid Enzymes, 1990, 35, 2191., Koizumi, M. et al., Nucl Acids Res, 1989, 17, 7059 .).

  Hairpin ribozymes are also useful for the purposes of the present invention. This ribozyme is found, for example, in the minus strand of tobacco ring spot virus satellite RNA (Buzayan, JM., Nature, 1986, 323, 349.). It has been shown that hairpin ribozymes can also produce target-specific RNA-cleaving ribozymes (Kikuchi, Y. & Sasaki, N., Nucl Acids Res, 1991, 19, 6751., Hiroshi Kikuchi, Chemistry and Biology, 1992, 30, 112.). In this way, by specifically cleaving the transcript of the gene encoding the above chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, or sulfotransferase using ribozyme, Expression can be inhibited.

  Inhibition of endogenous gene expression can also be carried out by RNA interference (RNA interference, hereinafter abbreviated as “RNAi”) using double-stranded RNA having the same or similar sequence as the target gene sequence.

  With the completion of genome projects in recent years, the entire human base sequence has been deciphered and many disease-related genes have been actively identified. Currently, therapeutic methods and drug development targeting specific genes are being actively implemented. Of particular interest is the application of small interfering RNA (siRNA), which exhibits specific post-transcriptional repression effects, to gene therapy. RNAi is a technique that is currently attracting attention because when a double-stranded RNA (dsRNA) is directly taken into a cell, expression of a gene having a sequence homologous to this dsRNA is suppressed. In mammalian cells, it is possible to induce RNAi by using short dsRNA (siRNA). RNAi is more stable, easier to experiment, and less expensive than knockout mice. Has many advantages.

  RNAi is a phenomenon discovered by Fire et al. In 1998 (Fire A, Nature (1998) 391,: 806-811), which strongly suppresses the expression of target genes with double-stranded RNA homology. That's it. Recently, it has attracted attention because it is simpler than conventional gene transfer methods using vectors and the like, has high specificity for a target, and can be applied to gene therapy.

  A nucleic acid having an inhibitory action by the RNAi effect is generally also called siRNA or shRNA. RNAi is a short double-stranded RNA (hereinafter abbreviated as “dsRNA”) consisting of a sense RNA consisting of a sequence homologous to the mRNA of the target gene and an antisense RNA consisting of a complementary sequence to the cell. This is a phenomenon that induces destruction by specifically and selectively binding to the target gene mRNA, and efficiently inhibiting (suppressing) the expression of the target gene by cleaving the target gene. For example, when dsRNA is introduced into a cell, expression of a gene having a homologous sequence with that RNA is suppressed (knocked down). Since RNAi can suppress the expression of target genes in this way, it can be used as a simple gene knockout method to replace conventional complicated and low efficiency homologous recombination methods, or a method applicable to gene therapy. It is attracting attention as. The RNA used for RNAi is not necessarily completely identical to the above-mentioned chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, or a gene encoding a sulfotransferase, or a partial region of the gene. , Preferably having complete homology.

  In designing siRNA, the target is not particularly limited as long as it is a gene encoding the above-mentioned chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, or sulfate transferase, and any region can be used. Can be all target candidates. For example, the base sequence of the Versican gene (SEQ ID NO: 3), the base sequence of the C4ST-1 gene (SEQ ID NO: 45), the base sequence of the C4ST-2 gene (SEQ ID NO: 47), the C4ST-3 gene It can be created based on the base sequence (SEQ ID NO: 49). More specifically, a partial region of the sequence can be a target candidate. For example, a partial region of the base sequence of the Versican gene (SEQ ID NO: 57), the C4ST-1 gene Partial region of the base sequence (SEQ ID NO: 58), partial region of the base sequence of the C4ST-2 gene (SEQ ID NO: 59), partial region of the base sequence of the C4ST-3 gene (SEQ ID NO: 60), C6ST -1 gene partial region (SEQ ID NO: 61), C6ST-2 gene partial region (SEQ ID NO: 62), GalNAc4ST-1 gene partial region (SEQ ID NO: 61) 63), a partial region of the base sequence of the GalNAc4ST-2 gene (SEQ ID NO: 64), a partial region of the base sequence of GALNAC4S-6ST (SEQ ID NO: 65), and the like. More specifically, siRNA targeting the DNA sequence specifically shown by this specification (SEQ ID NOs: 67 to 70) can be exemplified.

  In order to introduce siRNA into a cell, a method in which siRNA synthesized in vitro is linked to plasmid DNA and introduced into the cell, a method in which two RNAs are annealed, or the like can be employed.

  The two RNA molecules may be molecules having a structure in which one end is closed, for example, an siRNA (shRNA) having a hairpin structure. shRNA is an RNA molecule called a short hairpin RNA (short hairpin RNA), which has a stem-loop structure so that a part of a single strand forms a complementary strand with another region. That is, molecules capable of forming a double-stranded RNA structure within the molecule are also included in the siRNA of the present invention.

  Further, as a preferred embodiment of the present invention, RNA (siRNA) capable of suppressing the expression of Versican, C4ST-1, C4ST-2, C4ST-3 and the like by the RNAi effect, which is specifically described in the present specification. In the siRNA targeting the indicated DNA sequence (SEQ ID NOs: 67 to 70), for example, the above-mentioned chondroitin sulfate proteoglycan even if it is a double-stranded RNA having a structure in which one or a small number of RNAs are added or deleted Of the present invention are included in the siRNA of the present invention as long as they have a function of suppressing the expression of a gene encoding a core protein, a synthase, a desulfase inhibitor protein, or a sulfotransferase.

  RNA used for RNAi (siRNA) does not have to be completely identical (homologous) to the gene encoding the protein or a partial region of the gene, but may have perfect identity (homology) preferable.

  The details of the RNAi mechanism are still unknown, but an enzyme called DICER (a member of the RNase III nuclease family) contacts double-stranded RNA, and the double-stranded RNA is called a small interfering RNA or siRNA. It is thought to be broken down into pieces. The double-stranded RNA having the RNAi effect in the present invention includes a double-stranded RNA before being degraded by DICER as described above. That is, it is expected that even a long-chain RNA that does not have an RNAi effect with the same length is decomposed into siRNA having an RNAi effect in a cell. The length is not particularly limited.

  For example, a long double-stranded RNA corresponding to the full-length or almost full-length region of the above-mentioned chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase-inhibiting protein, or gene encoding a sulfotransferase, It is possible to decompose with DICER in advance and use the degradation product as the drug of the present invention. This degradation product is expected to contain a double-stranded RNA molecule (siRNA) having an RNAi effect. According to this method, a region on mRNA that is expected to have an RNAi effect need not be selected. That is, the region on the mRNA of the above-mentioned gene of the present invention having the RNAi effect does not necessarily need to be accurately defined.

  The above-mentioned “double-stranded RNA that can be suppressed by the RNAi effect” of the present invention means, in those skilled in the art, the above-mentioned chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, which is a target of the double-stranded RNA, Or it can produce suitably based on the base sequence of the gene which codes a sulfotransferase. For example, the double-stranded RNA of the present invention can be prepared based on the base sequence shown in SEQ ID NO: 67. That is, on the basis of the base sequence set forth in SEQ ID NO: 67, selecting any continuous RNA region of mRNA that is a transcription product of the sequence, and preparing a double-stranded RNA corresponding to this region, For those skilled in the art, it can be appropriately performed within the range of normal trials. In addition, selection of siRNA sequences having a stronger RNAi effect from mRNA sequences that are transcripts of the sequences can also be appropriately performed by those skilled in the art by known methods. If one strand is known, those skilled in the art can easily know the base sequence of the other strand (complementary strand). The siRNA can be appropriately prepared by those skilled in the art using a commercially available nucleic acid synthesizer. In addition, for synthesis of a desired RNA, a general synthesis contract service can be used.

  In addition, the siRNA in the present invention is not necessarily a set of double-stranded RNAs for the target sequence, and may be a mixture of a plurality of sets of double-stranded RNA for the region containing the target sequence. Here, siRNA as a nucleic acid mixture corresponding to the target sequence can be appropriately prepared by a person skilled in the art using a commercially available nucleic acid synthesizer and a DICER enzyme. Synthetic contract service can be used. The siRNA of the present invention includes so-called “cocktail siRNA”.

  In the siRNA of the present invention, not all nucleotides are necessarily ribonucleotides (RNA). That is, in the present invention, the one or more ribonucleotides constituting the siRNA may be corresponding deoxyribonucleotides. This “corresponding” refers to the same base species (adenine, guanine, cytosine, thymine (uracil)) although the structures of the sugar moieties are different. For example, deoxyribonucleotide corresponding to ribonucleotide having adenine refers to deoxyribonucleotide having adenine. The “plurality” is not particularly limited, but preferably refers to a small number of about 2 to 5.

  Furthermore, a DNA (vector) capable of expressing the RNA of the present invention is also included in a preferred embodiment of the compound capable of suppressing the expression of the gene encoding the above-described protein of the present invention. For example, the DNA (vector) capable of expressing the double-stranded RNA of the present invention is a DNA encoding one strand of the double-stranded RNA and a DNA encoding the other strand of the double-stranded RNA, Each DNA has a structure linked to a promoter so that it can be expressed. Those skilled in the art can appropriately prepare the above DNA of the present invention by general genetic engineering techniques. More specifically, the expression vector of the present invention can be prepared by appropriately inserting DNA encoding the RNA of the present invention into various known expression vectors.

  In addition, the expression inhibitory substance of the present invention includes the above-mentioned chondroitin sulfate proteoglycan core protein, synthase, desulfurase inhibitor protein, or an expression regulatory region of a gene encoding a sulfotransferase (for example, a promoter region. As an example, the above-mentioned chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor can be inhibited by binding to the PG-Lb promoter region, which is the base sequence represented by SEQ ID NO: 66). Compounds that inhibit the expression of a protein or gene encoding a sulfotransferase are included. The compound uses, for example, the above-mentioned chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, or promoter DNA fragment of a gene encoding a sulfotransferase, and the binding activity with the DNA fragment is used as an indicator. The screening method can be used. Further, those skilled in the art know whether or not to inhibit the expression of a gene encoding the above-mentioned chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, or sulfotransferase, for a desired compound. This method can be appropriately carried out by, for example, a reporter assay method.

  Further, the DNA (vector) capable of expressing the RNA of the present invention also expresses the above-described chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, or sulfate transferase gene encoding the present invention. Are included in preferred embodiments of the compounds capable of inhibiting For example, the DNA (vector) capable of expressing the double-stranded RNA of the present invention is a DNA encoding one strand of the double-stranded RNA and a DNA encoding the other strand of the double-stranded RNA, respectively. It is a DNA having a structure linked to a promoter so that it can be expressed. Those skilled in the art can appropriately prepare the above DNA of the present invention by general genetic engineering techniques. More specifically, the expression vector of the present invention can be prepared by appropriately inserting DNA encoding the RNA of the present invention into various known expression vectors.

  A preferred embodiment of the vector of the present invention includes a vector that expresses RNA (siRNA) capable of suppressing the expression of Versican, C4ST-1, C4ST-2, C4ST-3, etc. by the RNAi effect. .

  The above-mentioned chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor compound, or antibody that binds to a sulfotransferase can be prepared by methods known to those skilled in the art. If it is a polyclonal antibody, it can obtain as follows, for example. A small animal such as a rabbit is immunized with a recombinant (recombinant) protein expressed in a microorganism as a fusion protein with the above-mentioned natural protein or a GST, or a partial peptide thereof to obtain serum. Coupling this with, for example, ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography, core protein of the above chondroitin sulfate proteoglycan, synthetic enzyme, desulfating enzyme inhibitory compound, or sulfotransferase or synthetic peptide It is prepared by purifying with an affinity column or the like. In the case of a monoclonal antibody, for example, the above chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor compound, or sulfotransferase or a partial peptide thereof is immunized to a small animal such as a mouse, and the spleen is obtained from the mouse. And the cells are separated by grinding, and the cells and mouse myeloma cells are fused using a reagent such as polyethylene glycol, and the above chondroitin sulfate proteoglycan is obtained from the fused cells (hybridoma) formed thereby. Clones that produce antibodies that bind to the core protein, synthetic enzyme, desulfase inhibitor compound, or sulfotransferase of Subsequently, the obtained hybridoma is transplanted into the abdominal cavity of the mouse, and ascites is collected from the mouse, and the obtained monoclonal antibody is obtained by, for example, ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography, the above chondroitin. It can be prepared by purification using an affinity column coupled with a proteoglycan sulfate core protein, a synthetic enzyme, a desulfating enzyme inhibitory compound, or a sulfotransferase protein or a synthetic peptide.

  The antibody of the present invention is not particularly limited as long as it binds to the above-described chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor compound, or sulfate group transferase of the present invention. In addition to the above, a human antibody, a humanized antibody by genetic recombination, an antibody fragment thereof, or an antibody modification product thereof may be used.

  The protein of the present invention used as a sensitizing antigen for antibody acquisition is not limited with respect to the animal species from which it is derived, but is preferably a protein derived from a mammal such as a mouse or human, and particularly preferably a protein derived from a human. Human-derived proteins can be appropriately obtained by those skilled in the art using the gene sequences or amino acid sequences disclosed in the present specification.

  In the present invention, the protein used as the sensitizing antigen may be a complete protein or a partial peptide of the protein. Examples of the partial peptide of protein include an amino group (N) terminal fragment and a carboxy (C) terminal fragment of protein. As used herein, “antibody” means an antibody that reacts with the full length or fragment of a protein.

  In addition to immunizing non-human animals with antigens to obtain the above hybridomas, human lymphocytes such as human lymphocytes infected with EB virus are sensitized with proteins, protein-expressing cells or lysates thereof in vitro. Lymphocytes can be fused with human-derived myeloma cells having permanent mitotic activity, such as U266, to obtain hybridomas that produce desired human antibodies having binding activity to proteins.

  The above-mentioned chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor compound, or antibody to sulfotransferase of the present invention is expected to inhibit the expression or function of the protein by binding to the protein. Is done. When the obtained antibody is used for the purpose of administering it to the human body (antibody treatment), a human antibody or a humanized antibody is preferred in order to reduce immunogenicity.

  Furthermore, the present invention provides the above chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfurization as a substance capable of inhibiting the function of the above chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfating enzyme inhibitory compound, or sulfotransferase. It also contains a low molecular weight substance (low molecular weight compound) that binds to an oxidase inhibiting compound or a sulfotransferase. The low molecular weight substance may be a natural or artificial compound. Usually, it is a compound that can be produced or obtained by using methods known to those skilled in the art. The compound of the present invention can also be obtained by the screening method described later.

  Furthermore, as a substance capable of inhibiting the expression or function of the above-mentioned chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, or sulfotransferase of the present invention, the above chondroitin sulfate proteoglycan core protein, synthetic enzyme, Examples thereof include a desulfurase inhibitor protein or a mutant (dominant negative protein) having a dominant negative property with respect to a sulfotransferase. “The chondroitin sulfate proteoglycan core protein, synthase, desulfase-inhibiting protein, or the protein variant having a dominant negative property to sulfate group” refers to the chondroitin sulfate proteoglycan core protein, synthase, desulfurization It refers to a protein having a function of eliminating or reducing the activity of an endogenous wild-type protein by expressing an oxidase-inhibiting protein or a gene encoding a sulfotransferase. Examples of such dominant negative proteins include Versican core protein mutants that competitively inhibit the binding to chondroitin sulfate with the wild-type Versican core protein.

  In the present invention, the tissue or cell that inhibits the production or accumulation of chondroitin sulfate proteoglycan is not particularly limited, but is preferably the retina choroid, and more preferably the vascular endothelial cell in the retina choroid.

  Compounds that inhibit the production or accumulation of chondroitin sulfate proteoglycans are expected to be agents for the treatment or prevention of retina choroidal neovascular diseases. Here, “treatment or prevention” does not necessarily need to have a complete therapeutic or prophylactic effect on tissues or cells that exhibit retina choroidal neovascularization, but may have a partial effect.

  In the present invention, the retina choroidal neovascularization disease is not particularly limited as long as it is a disease accompanied by retina choroidal neovascularization, but is preferably retina choroidal neovascularization disease, more preferably diabetic retinopathy, retinal vein occlusion, Examples include retinopathy of prematurity and age-related macular degeneration.

  The retina choroidal neovascularization inhibitor of this invention has the effect | action which suppresses retina choroidal neovascularization by inhibiting the production | generation or accumulation | storage of chondroitin sulfate proteoglycan which is the cause of reticulochoroid angiogenesis. Therefore, as a preferred embodiment of the present invention, for example, a therapeutic agent for retinal neovascularization, a therapeutic agent for diabetic retinopathy, a therapeutic agent for retinal vein occlusion, a premature infant, comprising the retina choroidal neovascularization inhibitor of the present invention as an active ingredient. A therapeutic agent for retinopathy or a therapeutic agent for age-related macular degeneration is provided.

  In addition, the “retinal choroidal neovascularization inhibitor” of the present invention can also be expressed as “retrochoroidal neovascularization therapeutic agent”, “retrochoroidal neovascularization improving agent” or the like. In the present invention, the “suppressor” can also be expressed as “medicine”, “pharmaceutical composition”, “therapeutic drug”, and the like.

  In addition, the “treatment” in the present invention includes a preventive effect that can suppress the occurrence of retina choroidal neovascularization in advance. Moreover, it is not necessarily limited to the case where it has a complete therapeutic effect with respect to the retina choroidal neovascularization expression cell (tissue), The case where it has a partial effect may be sufficient.

  The agent of the present invention can be mixed with a physiologically acceptable carrier, excipient, diluent or the like and administered orally or parenterally as a pharmaceutical composition. As oral preparations, dosage forms such as granules, powders, tablets, capsules, solvents, emulsions or suspensions can be used. As the parenteral preparation, dosage forms such as injections, drops, external preparations, eye drops or suppositories can be selected. Examples of injections include subcutaneous injections, intramuscular injections, intraperitoneal injections, intracranial injections, intranasal injections, intravitreal injections, and the like. Examples of the medicine for external use include a nasal administration agent or an ointment. The preparation technology for making the above-mentioned dosage form so as to include the drug of the present invention as the main component is known.

  For example, a tablet for oral administration can be produced by adding an excipient, a disintegrant, a binder, a lubricant, and the like to the drug of the present invention, mixing, and compressing and shaping. As the excipient, lactose, starch, mannitol or the like is generally used. As the disintegrant, calcium carbonate, carboxymethyl cellulose calcium and the like are generally used. As the binder, gum arabic, carboxymethylcellulose, or polyvinylpyrrolidone is used. As the lubricant, talc, magnesium stearate and the like are known.

  The tablet containing the drug of the present invention can be coated with a known coating for masking or enteric preparation. As the coating agent, ethyl cellulose, polyoxyethylene glycol, or the like can be used.

  An injection can be obtained by dissolving the drug of the present invention as a main component together with an appropriate dispersant, or dissolving or dispersing in a dispersion medium. Depending on the selection of the dispersion medium, either a water-based solvent or an oil-based solvent can be used. In order to use an aqueous solvent, distilled water, physiological saline, Ringer's solution, or the like is used as a dispersion medium. In the oil solvent, various vegetable oils and propylene glycol are used as a dispersion medium. At this time, a preservative such as paraben may be added as necessary. In addition, known isotonic agents such as sodium chloride and glucose can be added to the injection. Further, a soothing agent such as benzalkonium chloride or procaine hydrochloride can be added.

  Moreover, it can be set as an external preparation by making the chemical | medical agent of this invention into a solid, liquid, or semi-solid composition. About a solid or liquid composition, it can be set as an external preparation by setting it as the composition similar to what was described previously. A semi-solid composition can be prepared by adding a thickener to an appropriate solvent as required. As the solvent, water, ethyl alcohol, polyethylene glycol, or the like can be used. As the thickener, bentonite, polyvinyl alcohol, acrylic acid, methacrylic acid, or polyvinylpyrrolidone is generally used. A preservative such as benzalkonium chloride can be added to the composition. Also, a suppository can be obtained by combining an oily base material such as cacao butter or an aqueous gel base material such as a cellulose derivative as a carrier.

  When the agent of the present invention is used as a gene therapy agent, a method of administering a vector incorporating a nucleic acid in addition to a method of directly administering the agent of the present invention by injection can be mentioned. Examples of the vector include an adenovirus vector, an adeno-associated virus vector, a herpes virus vector, a vaccinia virus vector, a retrovirus vector, a lentivirus vector, and the like, and can be efficiently administered by using these virus vectors.

  It is also possible to introduce the drug of the present invention into a phospholipid vesicle such as a liposome and administer the vesicle. The endoplasmic reticulum holding siRNA or shRNA is introduced into a predetermined cell by the lipofection method. Then, the obtained cells are systemically administered, for example, intravenously or intraarterially. It can also be administered locally to the retina choroidal neovascularization tissue or the like. Although siRNA exhibits a very excellent specific post-transcriptional repression effect in vitro, it is rapidly degraded in vivo by nuclease activity in serum. Therefore, the limited duration in vivo has become a problem, and the development of an optimal and effective delivery system has been demanded. In a recent report (Takeshita F. PNAS. (2003) 102 (34) 12177-82, Minakuchi Y Nucleic Acids Reserch (2004) 32 (13) e109), bovine skin-derived atelocollagen forms a complex with nucleic acid, It has the effect of protecting nucleic acids from in vivo degrading enzymes, and is considered to be very suitable as an siRNA carrier. These are only examples, and the delivery method in the present invention is not limited to these.

The necessary amount (effective amount) of the drug of the present invention is administered to mammals including humans within the safe dose range. The dosage of the drug of the present invention can be appropriately determined finally based on the judgment of a doctor or veterinarian in consideration of the type of dosage form, administration method, patient age and weight, patient symptoms, and the like. For example, although it varies depending on age, sex, symptom, administration route, administration frequency, dosage form, for example, the dose in the case of adenovirus is about 10 ⁶ to 10 ¹³ per day, Administered at 8 week intervals.

  In order to introduce siRNA or shRNA into a target tissue or organ, a commercially available gene introduction kit (for example, Adeno Express: Clontech) can also be used.

  When the agent of the present invention is used, the application site or the type of the disease is not particularly limited as long as it is a disease that develops retina choroidal neovascularization. For example, retinal neovascular disease, diabetic retinopathy, retinal vein occlusion, immaturity Applicable for infant retinopathy and age-related macular degeneration. The above-mentioned diseases may be accompanied with other diseases.

  In addition, the present invention provides a screening method for a retina choroidal neovascularization inhibitor comprising selecting a substance having an action of inhibiting the production or accumulation of chondroitin sulfate proteoglycan from a test sample. By the screening method of the present invention, a candidate compound for a retina choroidal neovascularization inhibitor or a retina choroidal neovascularization inhibitor can be efficiently obtained.

A preferred embodiment of the screening method of the present invention is a screening method for a retina choroidal neovascularization inhibitor comprising a step of selecting a substance having the action described in any of the following (a) to (d).
(A) Degradation promoting action of chondroitin sulfate proteoglycan (b) Synthesis inhibition action of chondroitin sulfate proteoglycan (c) Desulfation action of chondroitin sulfate proteoglycan (d) Sulfation inhibition action of chondroitin sulfate proteoglycan

As a basic principle of screening common to these, a typical example includes one including the following steps.
(1) Chondroitin sulfate proteoglycan (CSPG) itself / or glycosaminoglycan (GAG) chain / cells that synthesize (generate) CSPG or GAG chain (2) Test compounds (for example, enormous compound live of pharmaceutical companies Rally)
(3) Method of detecting cut section of chondroitin sulfate proteoglycan (CSPG) / chondroitin sulfate proteoglycan (CSPG) amount / free glycosaminoglycan (GAG) amount The above three tools are used. The procedure of mixing (1) and (2) in a test tube or on a culture dish and detecting the effect simply by (3) is desirable.

  Hereinafter, embodiments of the screening method of the present invention will be exemplified. In the embodiments described below, the chondroitin sulfate proteoglycan used, the synthetic enzyme, the desulfating enzyme inhibitory compound, the sulfotransferase, the degradation promoting enzyme, and the desulfating enzyme are derived from humans, mice, rats, etc. However, it is not particularly limited to those derived from these. The part of the chondroitin sulfate proteoglycan is a component such as a glycosaminoglycan chain, a core protein, or a part thereof, and is not particularly limited.

  In addition, the test compound used in the embodiments described below is not particularly limited. For example, a single compound such as a natural compound, an organic compound, an inorganic compound, a protein, and a peptide, and expression of a compound library and a gene library Examples include products, cell extracts, cell culture supernatants, fermented microorganism products, marine organism extracts, plant extracts and the like.

  In addition, the “contact” to the test compound in the embodiment described below usually involves chondroitin sulfate proteoglycan, a part thereof, a synthase, a desulfase inhibitor compound, a sulfotransferase, a degradation promoting enzyme, or a desulfase enzyme. Although it is performed by mixing with a test compound, it is not limited to this method. For example, the above “contact” can be performed by bringing a cell expressing these proteins or a part thereof into contact with a test compound.

  In addition, examples of the origin of the “cell” in the embodiments described below include cells derived from human, mouse, rat, etc., but are not particularly limited to cells derived from these, and express proteins used in each embodiment. It is also possible to use microbial cells such as Escherichia coli and yeast transformed as described above. For example, “cells expressing chondroitin sulfate proteoglycan” include cells expressing an endogenous chondroitin sulfate proteoglycan gene or cells into which an exogenous chondroitin sulfate proteoglycan gene has been introduced and expressed. can do. A cell in which an exogenous chondroitin sulfate proteoglycan gene is expressed can be usually prepared by introducing an expression vector into which a chondroitin sulfate proteoglycan gene is inserted into a host cell. The expression vector can be prepared by general genetic engineering techniques.

  In the following description, the term “chondroitin sulfate proteoglycan core protein” means, for example, a matrix type chondroitin sulfate proteoglycan, a core protein such as aggrican, versican, neurocan, or brevican, or a membrane type chondroitin sulfate proteoglycan. For example, it is a core protein such as Decorin, Biglycan, Fibromodulin, PG-Lb. “Synthetic enzymes” include, for example, GalNAc4ST-1, GalNAc4ST-2, GALNAC4S-6ST, UA2OST, GalT-I, GalT-II, GlcAT-I, XylosylT and the like. In addition, “sulfotransferase” includes, for example, C4ST-1 (Chondroitin DN-acetylgalactosamine-4-O-sulfotransferase 1), C4ST-2 (Chondroitin DN-acetylgalactosamine-4-O-sulfotransferase 2), C4ST-3 (Chondroitin DN-acetylgalactosamine-4-O-sulfotransferase 3), D4ST, C6ST-1, C6ST-2 and the like. Examples of the “degradation promoting enzyme” include ADAMTS-1, ADAMTS-4, ADAMTS-5, Chondroitinase ABC (ChABC), Chondroitinase AC, Chondroitinase B, and Calpain I. Examples of “desulfating enzyme” include Chondroitin-4-sulfatase, Chondroitin-6-sulfatase, and the like.

As an aspect of the screening method of the present invention, a method including a step of selecting a compound having an action of promoting the degradation of chondroitin sulfate proteoglycan can be mentioned. The above method of the present invention comprises, for example, the following steps.
(A) a step of contacting a test compound with chondroitin sulfate proteoglycan or a part thereof (b) a step of measuring the abundance of chondroitin sulfate proteoglycan or a part thereof (c) when measured in the absence of the test compound The process of selecting substances that reduce the abundance in comparison

  In the above method, first, a test compound is brought into contact with chondroitin sulfate proteoglycan or a part thereof.

  In the present method, the amount of chondroitin sulfate proteoglycan or a part thereof is then measured. The measurement can be performed by methods known to those skilled in the art. For example, it can be detected by measuring the amount of labeling using a labeled compound or antibody that binds to chondroitin sulfate proteoglycan or a part thereof. Moreover, it can also detect using a chromatography method, a mass spectrometry, etc.

  In this method, a compound that reduces the abundance of the chondroitin sulfate proteoglycan or a part thereof is then selected as compared with the case where the test compound is not contacted (control). The compound that lowers becomes a drug for treating choroidal neovascularization.

  A simple example of a method and a specific example that can be evaluated (measured) as to whether or not the test compound has the activity of the above-mentioned (a) decomposition promoting action is shown below.

(A) Screening method embodiment relating to the degradation promoting action of chondroitin sulfate proteoglycan:
As CS-GAG, chondroitin sulfate A (CS-A), CS-B, CS-C (Seikagaku, ICN, Sigma, etc.), human-derived proteoglycan (BGN, ISL, etc.), etc. are prepared. The 96-well plate is coated at a concentration of 10 μg / mL (by a known method such as Kawashima H et al .; J. Biol. Chem. 277: 12921-12930, 2002.). Various test compounds are added to each well of the plate, and changes in CS-GAG are detected after 2 hours of reaction at 37 ° C.

  As a detection method, for example, a WFA lectin (Nodafuji lectin) binding method can be mentioned as a simple method. Since WFA lectin binds to the GalNAc residue of CS-GAG chain, CS-GAG can be easily detected. Chondroitinase ABC is used as a positive control for the test compound. If chondroitinase ABC is added and the CS-GAG chain is degraded, WFA lectin cannot be bound, so the principle is used. More specifically, FITC-labeled WFA lectin (such as EY) is added to the CS-coated well before and after mixing the test compound, and CS-GAG is decomposed to change the FITC fluorescence intensity in the well. Quantification and quantification can be performed very easily using a detection device such as a fluorescence plate reader or a fluorescence microscope. A compound with the lowest fluorescence value before and after mixing can be determined as a novel therapeutic candidate compound that satisfies this concept.

  As another detection method, an anti-CS antibody (clone: CS56, manufactured by Seikagaku Corporation) that directly labels CS-GAG itself can be used. Similar to WFA lectin, FITC-labeled anti-CS antibody can be added to CS-coated wells, and large-scale screening can be performed in a very short time and simply if changes in fluorescence values are observed.

  As a more detailed detection method, use the sGAG Assay Kit (manufactured by WIESLAB), Sulphanated Glycosaminoglycans, ELISA Kit (manufactured by FUNAKOSHI), etc. by using the plate before and after mixing of the test compound as it is, and accurately determine the GAG content. There are methods to quantify and quantify.

  More specifically, by adding 2-AB (2-aminobenzamide) or 2-AP (2-aminopyridine; both from LUD, etc.) to the plate before and after mixing the test compound, the reducing end of the free GAG chain is More detailed analysis is possible by simply fluorescently labeling and analyzing each type of sugar chain and the content of each type by HPLC, MALDI-MS, LC-MS, etc. This is a method for the next stage of screening, in which the characteristics of candidate compounds are examined in detail.

As another aspect of the screening method of the present invention, there can be mentioned a method comprising a step of selecting a substance having an inhibitory action on chondroitin sulfate proteoglycan synthesis. The above method of the present invention comprises, for example, the following steps.
(A) contacting a test compound with a substance group containing a cell expressing chondroitin sulfate proteoglycan or a part thereof, the cell extract, or an enzyme and a substrate constituting the synthesis process of chondroitin sulfate proteoglycan (b) A step of measuring a synthesis amount of chondroitin sulfate proteoglycan or an intermediate in a synthesis process thereof in a cell, a cell extract or a substance group (c) a compound which decreases the synthesis amount compared to a case where a test compound is not contacted Process to select

  In the above method, first, a test compound is brought into contact with a substance group containing a cell expressing chondroitin sulfate proteoglycan or a part thereof, the cell extract, or an enzyme and a substrate constituting a synthesis process of chondroitin sulfate proteoglycan.

  Next, the synthesis amount of chondroitin sulfate proteoglycan or an intermediate in the synthesis process thereof is measured. The measurement can be appropriately performed by those skilled in the art by a known method such as a method using a labeled antibody, mass spectrometry, chromatography, or the like.

  Further, a compound that reduces (suppresses) the amount of synthesis is selected as compared with the case where the test compound is not contacted (control). A compound that lowers (suppresses) becomes a drug for treating choroidal neovascularization.

  A simple example of a method and a specific example capable of evaluating (measuring) whether or not the test compound has the activity of the above-mentioned (b) synthesis inhibitory action is shown below.

(B) Screening method for the chondroitin sulfate proteoglycan synthesis inhibitory action:
Cells and cell lines that synthesize chondroitin sulfate are known to the investigator. In humans, for example, chondroitin sulfate is produced in 16 hours of cell culture by the standard method of separating and culturing mononuclear cells after collecting peripheral blood from healthy individuals (Uhlin-Hansen L et al., Blood 82: 2880, 1993.). More simply, known cell lines such as fibroblast cell line NIH3T3 (Phillip HA, et al. J. Biol. Chem. 279: 48640, 2004, etc.), renal tubule-derived cancer cell line ACHN (Kawashima H et al., J. Biol. Chem. 277: 12921, 2002), distal renal tubular cell line MDCK (Borges FT et al., Kidney Int. 68: 1630, 2005., etc.), vascular endothelial cell line Many examples include HUVEC (Schick BP et al., Blood 97: 449, 2001, etc.). In the process of culturing such a cell line for a certain period of time, various test compounds are mixed, and the change in the CS-GAG amount before and after the culture can be easily quantified by the method (a). A compound that suppresses an increase in the amount of CS-GAG after cell culture (ie, reflects the amount of CS-GAG synthesis) can be easily determined as a therapeutic candidate compound that satisfies this concept.

  Furthermore, more selectively, for example, a cell line in which CS-GAG synthase genes such as GalNAc4ST-1 and XylosylT are introduced into CHO cells and L cells by a well-known method and expressed constantly can be prepared. it can. By using such a cell line that constantly synthesizes CS-GAG, it is possible to more clearly determine a therapeutic candidate compound.

As another aspect of the screening method of the present invention, there may be mentioned a method comprising a step of selecting a substance having a desulfating action of chondroitin sulfate proteoglycan. The above method of the present invention comprises, for example, the following steps.
(A) a step of contacting a test compound with chondroitin sulfate proteoglycan or a part thereof (b) a step of measuring the amount of chondroitin sulfate proteoglycan or a part thereof subjected to sulfation (c) in the absence of the test compound The process of selecting substances that reduce the amount of sulfation compared to when measured in

  In the above method, first, a test compound is brought into contact with chondroitin sulfate proteoglycan or a part thereof.

  In this method, the amount of chondroitin sulfate proteoglycan or a part thereof that has undergone sulfation is then measured. The measurement can be performed by methods known to those skilled in the art. For example, it can be detected by measuring the amount of label using a labeled compound or antibody that binds to the desulfated structure remaining in chondroitin sulfate proteoglycan or a part thereof. Moreover, it can also detect using a chromatography method, a mass spectrometry, etc.

  In this method, a compound that reduces the abundance of the chondroitin sulfate proteoglycan or a part thereof is then selected as compared with the case where the test compound is not contacted (control). The compound that lowers becomes a drug for treating choroidal neovascularization.

  A simple example of a method and a specific example that can be evaluated (measured) as to whether or not the test compound has the activity (c) desulfation activity is shown below.

(C) Screening method aspect regarding desulfation action of chondroitin sulfate proteoglycan:
Basically, human-derived proteoglycan (BGN, ISL, etc.) is prepared in the same manner as in the above method (a) and coated on a 96-well plate at a concentration of 10 μg / mL (Kawashima H et al .; J. Biol Chem. 277: 12921-12930, 2002. etc.)). Various test compounds are added to each well of the plate, and changes in CS-GAG are detected after 2 hours of reaction at 37 ° C.

  The detection method is to desulfate the disaccharide structure of the desulfated fragment remaining on the core protein side of the proteoglycan into the anti-proteoglycan Δdi4S antibody (clone; 2-B-6, the portion that had been sulfated at position 4 Or a part that has undergone desulfation by reacting with anti-proteoglycan Δdi6S (clone; 3-B-3, which recognizes the part that was sulphated at position 6. Both are manufactured by Seikagaku Corporation) Can be easily detected. Therefore, FITC-labeled 2-B-6 and 3-B-3 antibodies are reacted on the plate before and after mixed culture, and the change in the fluorescence value can be easily detected. A compound with increased fluorescence intensity before and after the reaction can be determined to be a substance that further promotes desulfation, and can be easily identified as a novel therapeutic candidate compound that satisfies this concept.

As another aspect of the screening method of the present invention, there may be mentioned a method comprising a step of selecting a substance having a sulfation inhibitory action of chondroitin sulfate proteoglycan. The above method of the present invention comprises, for example, the following steps.
(A) a step of contacting a test compound with a substance group containing a chondroitin sulfate proteoglycan or a cell or cell extract expressing the chondroitin sulfate proteoglycan or an enzyme, a substrate, etc. constituting the sulfation process of chondroitin sulfate proteoglycan (b) , A step of measuring the sulfation activity of chondroitin sulfate proteoglycan in a cell extract or substance group (c) a step of selecting a compound that decreases the activity compared to the case where no test compound is contacted

  In the above method, first, a test substance is brought into contact with chondroitin sulfate proteoglycan or a part thereof.

  In this method, the amount of chondroitin sulfate proteoglycan or a part thereof that has undergone sulfation is then measured. The measurement can be performed by methods known to those skilled in the art. For example, it can be detected by measuring the amount of labeling using a labeled compound or antibody that binds to chondroitin sulfate proteoglycan or a sulfated structure of a part thereof. Moreover, it can also detect using a chromatography method, a mass spectrometry, etc.

  In this method, a compound that reduces the abundance of the chondroitin sulfate proteoglycan or a part thereof is then selected as compared with the case where the test compound is not contacted (control). The compound that lowers becomes a drug for treating choroidal neovascularization.

  A simple example of a method and a specific example capable of evaluating (measuring) whether or not the test compound has the above-mentioned (d) activity of inhibiting sulfation is shown below.

(D) Screening method aspect regarding the sulfation inhibitory action of chondroitin sulfate proteoglycan:
The cells and cell lines that promote sulfation of chondroitin sulfate match the cells and cell lines described in (c) above. In the process of culturing such cell lines for a certain period of time, various test compounds are mixed, and the degree of sulfation before and after culturing is measured, for example, the antibody that detects 4-position sulfation (clone: LY111) or the 6-position sulfation The antibody to be detected (clone; MC21C, both manufactured by Seikagaku Corporation) can be easily confirmed. Fluorescence-labeled antibodies may be used to compare fluorescence values before and after culture. Similarly to (c) above, detection methods using 2-B-6 and 3-B-3 antibodies may be performed before and after culture. Also good. Compounds that suppress the increase in sulfation after cell culture (LY111 and MC21C fluorescence values increase), or promote the progress of desulfation after cell culture (2-B-6 and 3-B-3 fluorescence values increase) Can be easily determined as a therapeutic candidate compound that satisfies this concept.

  Furthermore, more selectively, for example, a cell line in which a sulfated transferase gene such as C4ST-1 or C6ST-1 is introduced into CHO cells or L cells by a well-known method and expressed constantly is prepared. Can do. By using such a cell line to which a sulfate group is constantly added, a treatment candidate compound can be determined more clearly.

Another preferred embodiment of the present invention is a compound that decreases the expression level of the chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, or sulfotransferase gene of the present invention, or promotes the degradation of chondroitin sulfate proteoglycan It is a screening method for a retina choroidal neovascularization inhibitor comprising the following steps (a) to (d), wherein a compound that increases the expression level of an enzyme or a desulfating enzyme gene is selected.
(A) contacting a test compound with a cell expressing a gene encoding a chondroitin sulfate proteoglycan core protein, a synthetic enzyme, a desulfase inhibitor protein, a sulfotransferase, a degradation accelerating enzyme, or a desulfase enzyme (b) ) A step of measuring the expression level of a gene in the cell (c) a step of comparing the expression level with a case where the expression level is measured in the absence of a test compound (control) (d) a core protein of chondroitin sulfate proteoglycan, In the case of a synthetic enzyme, a desulfurase inhibitor protein, or a sulfotransferase, a compound in which the expression level of the gene is reduced compared to the control, the gene is a chondroitin sulfate proteoglycan degradation-promoting enzyme, or desulfurization In the case of an oxidase, the expression level of the gene is increased compared to the control. Selecting a compound that are

  In the above method, first, a test compound is brought into contact with a cell expressing a gene encoding a chondroitin sulfate proteoglycan core protein, a synthetic enzyme, a desulfase inhibitor protein, a sulfotransferase, a degradation promoting enzyme, or a desulfase enzyme. .

  Next, in the present method, the expression level of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfotransferase, degradation promoting enzyme, or desulfase is measured. Here, “gene expression” includes both transcription and translation. The gene expression level can be measured by methods known to those skilled in the art.

  For example, mRNA is extracted from cells expressing any of the above proteins according to a conventional method, and the transcription amount of the gene is determined by performing Northern hybridization, RT-PCR, DNA array, etc. using this mRNA as a template. Measurements can be made. In addition, by collecting a protein fraction from a cell expressing a gene encoding any of the above proteins and detecting the expression of any of the above proteins by electrophoresis such as SDS-PAGE, the amount of translation of the gene can be reduced. Measurements can also be made. Furthermore, the amount of translation of a gene can be measured by detecting the expression of the protein by performing Western blotting using an antibody against any of the above proteins. The antibody used for detection of the protein is not particularly limited as long as it is a detectable antibody. For example, both a monoclonal antibody and a polyclonal antibody can be used.

  In this method, the expression level of the gene is then compared with the case where the test compound is not contacted (control).

  In this method, when the gene is a chondroitin sulfate proteoglycan core protein, a synthase, a desulfase-inhibiting protein, or a sulfotransferase, the expression level of the gene is decreased compared to the control ( Select the compound being suppressed. The compound to be reduced (suppressed) becomes a drug for suppressing choroidal neovascularization or a candidate compound for treating choroidal neovascularization.

  In addition, when the gene is a chondroitin sulfate proteoglycan degradation promoting enzyme or a desulfating enzyme, a compound whose expression level of the gene is increased (enhanced) compared to the control is selected. The compound to be increased (enhanced) becomes a drug for suppressing retina choroidal neovascularization or a candidate compound for treating retina choroidal neovascularization.

In addition, as one aspect of the screening method of the present invention, the chondroitin sulfate proteoglycan core protein, the synthetic enzyme, the desulfase inhibitor protein, or the compound that decreases the expression level of the sulfotransferase gene, or chondroitin sulfate In this method, a compound that increases the expression level of a proteoglycan degradation-promoting enzyme or desulfating enzyme gene is selected using the expression of a reporter gene as an index. The method of the present invention includes, for example, the following steps (a) to (d).
(A) Structure in which a transcriptional regulatory region of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfate transferase, degradation promoting enzyme, or desulfase is functionally linked to a reporter gene (B) a step of contacting a test compound with a cell or cell extract containing DNA having DNA (b) a step of measuring the expression level of the reporter gene (c) a step of comparing with a case where the test compound is not contacted (control) d) When the reporter gene is functionally linked to a chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, or sulfotransferase, the expression level of the reporter gene is compared to the control. Compound, the reporter gene is chondroit When operatively linked to degradation-promoting enzyme or desulfating enzymes, sulfate proteoglycans step of selecting compounds that expression levels of the reporter gene is increased as compared with the control

  In this method, first, a chondroitin sulfate proteoglycan core protein, a synthetic enzyme, a desulfase inhibitor protein, a sulfotransferase, a degradation promoting enzyme, or a transcriptional regulatory region of a gene encoding a desulfase, and a reporter gene are functionally functional. A test compound is brought into contact with a cell or cell extract containing DNA having a bound structure.

  Here, “functionally linked” means transcription into the transcriptional regulatory region of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfotransferase, degradation promoting enzyme, or desulfase. A gene that encodes chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, sulphate transferase, degradation promoting enzyme, or desulfatase so that expression of the reporter gene is induced by binding of the factor The transcriptional regulatory region and the reporter gene. Therefore, even when the reporter gene is linked to other genes and forms a fusion protein with other gene products, chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, sulfate transferase If the expression of the fusion protein is induced by binding of a transcription factor to the transcriptional regulatory region of a gene encoding a degradation-promoting enzyme or desulfating enzyme, the above-mentioned “functionally bound” means include. Based on the cDNA base sequence of the gene encoding chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, sulfate transferase, degradation-promoting enzyme, or desulfase, it exists in the genome for those skilled in the art It is possible to obtain a transcriptional regulatory region of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfate transferase, degradation promoting enzyme, or desulfase, by a well-known method.

  The reporter gene used in this method is not particularly limited as long as its expression can be detected, and examples thereof include CAT gene, lacZ gene, luciferase gene, and GFP gene. “It has a structure in which a transcriptional regulatory region of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfate transferase, degradation promoting enzyme, or desulfase is functionally linked to a reporter gene. Examples of the “cell containing DNA” include a cell into which a vector having such a structure inserted is introduced. Such vectors can be prepared by methods well known to those skilled in the art. Introduction of the vector into the cells can be performed by a general method such as calcium phosphate precipitation, electric pulse perforation, lipofection, microinjection and the like. “It has a structure in which a transcriptional regulatory region of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfate transferase, degradation promoting enzyme, or desulfase is functionally linked to a reporter gene. The “cell containing DNA” also includes a cell in which the structure is inserted into a chromosome. The DNA structure can be inserted into the chromosome by a method generally used by those skilled in the art, for example, a gene introduction method using homologous recombination.

  “It has a structure in which a transcriptional regulatory region of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfate transferase, degradation promoting enzyme, or desulfase is functionally linked to a reporter gene. “A cell extract containing DNA” refers to, for example, a chondroitin sulfate proteoglycan core protein, a synthase, a desulfase-inhibiting protein, or a sulfotransferase in a cell extract contained in a commercially available in vitro transcription / translation kit. Examples include those to which DNA having a structure in which a transcriptional regulatory region of a gene and a reporter gene are functionally linked is added.

  Here, “contact” means that “the transcriptional regulatory region of a gene encoding chondroitin sulfate proteoglycan core protein, synthetic enzyme, desulfase inhibitor protein, sulfotransferase, degradation promoting enzyme, or desulfase enzyme and the reporter gene function. The test compound can be added to the culture solution of “cells containing DNA having a structure that has been chemically bound” or the test compound is added to the above-described commercially available cell extract containing the DNA. When the test compound is a protein, for example, it can be performed by introducing a DNA vector expressing the protein into the cell.

  In this method, the expression level of the reporter gene is then measured. The expression level of the reporter gene can be measured by methods known to those skilled in the art depending on the type of the reporter gene. For example, when the reporter gene is a CAT gene, the expression level of the reporter gene can be measured by detecting acetylation of chloramphenicol by the gene product. When the reporter gene is a lacZ gene, by detecting the color development of the dye compound catalyzed by the gene expression product, and when the reporter gene is a luciferase gene, the fluorescent compound catalyzed by the gene expression product By detecting fluorescence, and in the case of a GFP gene, the expression level of the reporter gene can be measured by detecting fluorescence due to the GFP protein.

  In this method, the expression level of the measured reporter gene is then compared with that measured in the absence of the test compound (control).

  In this method, when the reporter gene is functionally linked to a gene encoding chondroitin sulfate proteoglycan core protein, synthase, desulfase inhibitor protein, or sulfotransferase, then the reporter gene is used. A compound whose gene expression level is reduced (suppressed) compared to the control is selected. The compound to be reduced (suppressed) becomes a drug for suppressing choroidal neovascularization or a candidate compound for treating choroidal neovascularization.

  In addition, when the reporter gene is functionally bound to the chondroitin sulfate proteoglycan degradation promoting enzyme or desulfation enzyme, the expression level of the reporter gene is increased (enhanced) compared to the control. Select a compound. The compound to be increased (enhanced) becomes a drug for suppressing retina choroidal neovascularization or a candidate compound for treating retina choroidal neovascularization.

  The inhibitor of retina choroidal neovascularization found in the screening method of the present invention is preferably for treating or preventing a retina choroidal neovascularization disease.

  The present invention also provides a kit containing various drugs / reagents and the like used for carrying out the screening method of the present invention.

  The kit of the present invention can be appropriately selected from, for example, the above-mentioned various reagents of the present invention according to the screening method to be performed. For example, the kit of the present invention can contain the chondroitin sulfate proteoglycan of the present invention as a constituent element. The kit of the present invention can further contain various reagents, containers and the like used in the method of the present invention. For example, an anti-chondroitin sulfate proteoglycan antibody, a probe, various reaction reagents, cells, a culture solution, a control sample, a buffer solution, instructions describing how to use and the like can be appropriately included.

  In a preferred embodiment of the present invention, the present invention is a screening method for a choroidal neovascularization inhibitor comprising the step of detecting whether the production or accumulation of chondroitin sulfate proteoglycan is inhibited. Accordingly, in the screening method, for example, an oligonucleotide such as a probe for a gene encoding the core protein of chondroitin sulfate proteoglycan or a primer for amplifying an arbitrary region of the gene, which can be used when detecting chondroitin sulfate proteoglycan, Alternatively, an antibody that recognizes chondroitin sulfate proteoglycan (anti-chondroitin sulfate proteoglycan antibody) can also be included in the components of the kit for screening an inhibitor of choroidal neovascularization of the present invention.

  For example, the oligonucleotide specifically hybridizes to the DNA of the Versican core protein gene of the present invention. Here, “specifically hybridize” means normal hybridization conditions, preferably stringent hybridization conditions (for example, Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory Press, New York, USA, In the condition described in the second edition 1989), it means that cross-hybridization does not occur significantly with DNA encoding other proteins. If specific hybridization is possible, the oligonucleotide does not need to be completely complementary to the base sequence of the Versican core protein gene of the present invention.

  As hybridization conditions in the present invention, for example, “2 × SSC, 0.1% SDS, 50 ° C.”, “2 × SSC, 0.1% SDS, 42 ° C.”, “1 × SSC, 0.1% SDS, 37 ° C.” More stringent conditions include “2 × SSC, 0.1% SDS, 65 ° C.”, “0.5 × SSC, 0.1% SDS, 42 ° C.” and “0.2 × SSC, 0.1% SDS, 65 ° C.” Can do. More specifically, as a method using Rapid-hyb buffer (Amersham Life Science), prehybridization is performed at 68 ° C for 30 minutes or more, and then a probe is added and kept at 68 ° C for 1 hour or more for hybridization. Then wash 3 times for 20 minutes at room temperature in 2 x SSC, 0.1% SDS, then 3 times for 20 minutes at 37 ° C in 1 x SSC, 0.1% SDS, and finally 1 x SSC Washing can be performed twice in 0.1% SDS at 50 ° C for 20 minutes. In addition, for example, prehybridization in Expresshyb Hybridization Solution (CLONTECH) for 30 minutes or more at 55 ° C, add labeled probe, and incubate at 37-55 ° C for 1 hour or more, in 2 × SSC, 0.1% SDS In addition, washing for 20 minutes at room temperature can be performed three times, and washing for 20 minutes at 37 ° C. in 1 × SSC and 0.1% SDS can be performed once. Here, for example, by setting the temperature at the time of pre-hybridization, hybridization, or the second washing higher, the conditions can be made more stringent. For example, the prehybridization and hybridization temperatures can be 60 ° C., and the stringent conditions can be 68 ° C. Those skilled in the art can set conditions by considering other conditions such as probe concentration, probe length, probe base sequence configuration, reaction time, etc. in addition to such conditions as buffer salt concentration and temperature. can do.

  The oligonucleotide can be used as a probe or primer in the screening kit of the present invention. When the oligonucleotide is used as a primer, the length is usually 15 bp to 100 bp, preferably 17 bp to 30 bp. The primer is, for example, the one described in SEQ ID NO: 71 or 72, but is not particularly limited as long as it can amplify at least a part of the DNA of the gene in the present invention.

  The present invention also provides a method for treating or preventing a choroidal neovascularization disease, comprising the step of administering the agent of the present invention to an individual (for example, a patient).

  The individual subject to the prevention or treatment method of the present invention is not particularly limited as long as it is an organism that can develop a choroidal neovascularization disease, but is preferably a human.

  Administration to an individual can be generally performed by methods known to those skilled in the art, such as intraarterial injection, intravenous injection, and subcutaneous injection. The dosage varies depending on the weight and age of the patient, the administration method, etc., but a person skilled in the art (such as a doctor, veterinarian, pharmacist, etc.) can appropriately select an appropriate dosage.

  The present invention further relates to the use of the agent of the present invention in the manufacture of a retina choroidal neovascularization inhibitor.

  It should be noted that all prior art documents cited in the present specification are incorporated herein by reference.

  Hereinafter, the present invention will be described more specifically with reference to examples. However, the technical scope of the present invention is not limited to these examples.

Example 1: Effect of chondroitin-4-desulfase in Streptozotocin-induced type 2 diabetic retinopathy model mice: attenuation of sulfated CSPG:
Day 14 of pregnancy C57BL / 6JcL mice (CLEA Japan) were bred and born, 2 days after birth C57BL / 6JcL mice female (CLEA Japan), Streptozocin 10 mg / mL (SIGMA) 20 μL / Injected subcutaneously into the head, fed with CE-2 (CLEA Japan) and sterilized water until 4 weeks of age, and fed with High Fat Diet diet (CLEA Japan) and sterilized water from 4 weeks of age. Raised for a week. In the second week, chondroitin-4-desulfase (20 units / ml; manufactured by Seikagaku Corporation) at 4 units / mouse, and the solvent (phosphate buffer) was administered intraperitoneally twice a week (1 shot) (1 week) 4 times (2 weeks). On the 14th day, in order to examine the effect of chondroitin-4-desulfating enzyme, the eyes of both groups of mice were removed and subjected to immunohistological studies.

  Frozen blocks and sections were prepared with the removed eyes. Sections were fixed with acetone (Sigma Aldrich Japan) for 10 minutes, washed with phosphate buffer, and anti-chondroitin sulfate proteoglycan (CSPG) antibody (clone CS56, mouse monoclonal antibody, 10 μg / mL; biochemistry as primary antibody) Kogyo Co., Ltd.) was added and reacted at room temperature for 1 hour. Subsequently, a secondary antibody reaction was performed using a histofine mouse stain kit (manufactured by Nichirei; used for mouse monoclonal antibody), and then DAB substrate (manufactured by Nichirei) was added to perform an enzyme dye reaction. This specimen was observed using an optical microscope (Leica).

  The obtained tissue image is shown in FIG. 1 (the original image is in color). In the untreated group, a new CS56 positive finding is observed on the vitreous side of the retina. In contrast, the CS56 intensity in the enzyme treatment group is weakened. CS56 is an antibody that recognizes not only the 4-position but also the 6-position sulfate group, suggesting that this attenuation reflects the attenuation of the 4-position sulfate group. From the above, it was revealed that CSPG deposition in the retinal tissue induced in this model mouse was modified and suppressed by in vivo administration of chondroitin-4-desulfating enzyme.

Example 2: Effect of chondroitin-4-desulfase in Streptozotocin-induced type 2 diabetic retinopathy model mice: inhibition of vascular endothelial cell proliferation:
A section obtained by the same method as in Example 1 was fixed with acetone (manufactured by Sigma-Aldrich Japan) for 10 minutes, washed with a phosphate buffer, and rat-derived anti-vascular endothelial cell antibody (CD31; 1: 200 dilution; manufactured by Pharmingen) was added and allowed to react at room temperature for 1 hour. Next, peroxidase-labeled donkey-derived anti-rat IgG (1: 200 dilution; manufactured by Biosource), which is a secondary antibody, was added and reacted at room temperature for 30 minutes. DAB substrate (Nichirei) was added to the sample after the reaction. This specimen was observed using an optical microscope (Leica).

  The obtained tissue image is shown in FIG. 2 (the original image is in color). In the untreated group, the number of CD31 positive cells on the retinal vitreous side increased, and some images protruded into the vitreous body. This is considered to reflect the stage of preproliferative retinopathy of diabetic retinopathy, and shows the effectiveness of the model. In contrast, in the enzyme treatment group, the number of CD31 positive cells at the same site was clearly reduced. From the above results, it was suggested that in the type 2 diabetes model, the number of vascular endothelial cells on the retinal vitreous side increases, but administration of chondroitin-4-desulfating enzyme suppresses such vascular proliferation.

Example 3: Effect of chondroitin-4-desulfating enzyme in Streptozotocin-induced type 2 diabetic retinopathy model mice: inhibition of collagen-induced changes:
A section obtained by the same method as in Example 1 was fixed with acetone (manufactured by Sigma-Aldrich Japan) for 10 minutes, washed with a phosphate buffer, and a rabbit-derived anti-type IV collagen antibody (1: 250 dilution) as a primary antibody. And Sigma) were added and reacted at room temperature for 1 hour. Next, peroxidase-labeled anti-rabbit IgG (1: 200 dilution; manufactured by Jackson ImmunoResearch), which is a secondary antibody, was added and reacted at room temperature for 30 minutes. DAB substrate (Nichirei) was added to the sample after the reaction. This specimen was observed using an optical microscope (Leica).

  The obtained tissue image is shown in FIG. 3 (the original image is in color). In the untreated group, positive findings of type IV collagen were observed on the retinal vitreous side, and findings parallel to the intraretinal boundary membrane were observed. This suggests an increase in collagen, that is, a change in fibrosis, along with abnormal venous morphology. In contrast, in the enzyme treatment group, the growth of type IV collagen at the same site was remarkably suppressed. From the above results, it was revealed that retinal collagen growth was observed in the type 2 diabetes model but was suppressed by administration of chondroitin-4-desulfase.

Example 4: Versican gene silencing effect in Streptozotocin-induced type 2 diabetic retinopathy model mice: inhibition of versican expression enhancement:
Day 14 of pregnancy C57BL / 6JcL mice (CLEA Japan) were bred and born, 2 days after birth C57BL / 6JcL mice female (CLEA Japan), Streptozocin 10 mg / mL (SIGMA) 20 μL / Injected subcutaneously into the head, fed with CE-2 (CLEA Japan) and sterilized water until 4 weeks of age, and fed with High Fat Diet diet (CLEA Japan) and sterilized water from 4 weeks of age. Raised for a week. At 2 weeks, versican siRNA cocktail (5′-ATGAAAGGCATCTTATGGATGTGCTCA-3 ′ (SEQ ID NO: 67); 5′-ATTACTAACCCATGCACTACATCAA-3 ′ (SEQ ID NO: 68); 5′-GGCAGCCACCAGCAGGTACACTCTG-3 ′ (SEQ ID NO: 69); 5'-CTGCTCAACAGGCTTGTTTGGATAT-3 '(SEQ ID NO: 70), 1 μg / mouse, Gene World, or PBS mixed with atelocollagen (Kohken) diluted 10-fold with PBS in advance and injected 200 μl intraperitoneally did. Treatment was performed once (one week) and twice (2 weeks) by intraperitoneal administration (1 shot / one week). On day 14, the versican SiRNA effect was examined by PCR.

The collected eyeballs were frozen in 1.5 ml tubes, especially with liquid nitrogen. To 50 mg of tissue, add 1 ml of RNA-Bee (TEL-TEST) and homogenize the suspension, add 200 μl of chloroform (Sigma Aldrich Japan), mix gently, and cool on ice for about 5 minutes. Centrifugation was performed using a centrifuge (Centrifuge 5417R, manufactured by Eppendorf) for 15 minutes at rpm and 4 ° C. Transfer 500 μl of the supernatant after centrifugation to another 1.5 ml tube, add 500 μl of isopropannol (Sigma Aldrich Japan) equivalent to the supernatant, mix, add 1 μl glycogen (Invitrogen), and cool on ice for 15 minutes. did. After 15 minutes of ice cooling, centrifuge for 15 minutes at 12,000 rpm and 4 ° C, and then wash the RNA precipitate with 75% Ethanol 1000 μl (Sigma Aldrich Japan) three times for 30 minutes to 1 hour. After drying, dissolve in 50 μl of Otsuka distilled water (manufactured by Otsuka Pharmaceutical), further dilute 100 times with Otsuka distilled water, and plate reader (POWER Wave XS, BIO-TEK) on a UV plate (Corning Coaster). The RNA concentration in the sample extracted by the company was calculated. The obtained RNA sample was adjusted to a concentration of 500 ng / 20 μl, heated at 68 ° C. for 3 minutes with BLOCK INCUBATOR (manufactured by ASTEC), and cooled on ice for 10 minutes. RT premix solution (composition: 25 mM MgCl ₂ 18.64 μl (Invitrogen)), 5 × Buffer 20 μl (Invitrogen), 0.1 M DTT 6.6 μl (Invitrogen), 10 mM dNTP mix 10 μl (Invitrogen), RNase Inhibitor 2 μl (Invitrogen), MMLV Reverse transcriptase 1.2 μl (Invitrogen), Random primer 2 μl (Invitrogen), sterile distilled water 19.56 μl (Otsuka distilled water: Otsuka Pharmaceutical) And heated at 42 ° C. for 1 hour, 99 ° C. for 5 minutes, and then ice-cooled to prepare 100 μl of cDNA.

PCR reaction was performed with the following composition using the obtained cDNA.
PCR Buffer 2 μl [Composition: 166 mM (NH ₄ ) ₂ SO ₄ (Sigma Aldrich Japan), 670 mM Tris pH8.8 (Invitrogen), 67 mM MgCl ₂ · 6H ₂ O (Sigma Aldrich Japan), 100 mM 2 -mercaptoethanol (manufactured by WAKO)], 25 mM dNTP mix 0.8 μl (manufactured by Invitrogen), DMSO 0.6 μl (manufactured by Sigma Aldrich Japan), primer 0.2 μl (forwaed 5′-GACGACTGTCTTGGTGG-3 ′ (SEQ ID NO: 71), Reverse 5'-ATATCCAAACAAGCCTG-3 '(SEQ ID NO: 72), GeneWorld), Otsuka distilled water 15.7 μl, Taq polymerase 0.1 μl (Perkin Elmer), cDNA 1 μl mixed and Authorized Themal Cycler (eppendorf) The reaction was carried out for 35 cycles at 94 ° C for 45 seconds, 56 ° C for 45 seconds, and 72 ° C for 60 seconds. After completion of the reaction, 2 μl Loading Dye (Invitrogen) is added to the obtained PCR product to prepare a 1.5% UltraPure Agarose (Invitrogen) gel, and 100 V for 20 minutes using Mupid-2 plus (ADVANCE). Electrophoresis was performed. After electrophoresis, dilute 10,000 times with 1 × LoTE [Composition: 3 mM Tris-HCl (pH 7.5) (Invitrogen), 0.2 mM EDTA (pH 7.5) (Sigma Aldrich Japan)] Ethydium Bromide (Invitrogen) After shaking for 20 minutes to 30 minutes in a staining solution, gel expression was confirmed with EXILIM (manufactured by CASIO) installed in I-Scope WD (manufactured by ADVANCE) to confirm gene expression.

  FIG. 4 shows the results of semiquantitative PCR in which the dilution ratio of cDNA is roughly divided into 9 times and 18 times (1/9, 1/18). In the non-diabetic group, versican mRNA expression was enhanced, but in the versican siRNA treatment group, versican mRNA expression was not enhanced. This suppression of expression is noticeable at a dilution rate of 18 times. From the above, it was proved that administration of versican siRNA significantly suppresses versican expression enhancement associated with diabetic retinopathy.

Example 5: Versican gene silencing effect in Streptozotocin-induced type 2 diabetic retinopathy model mice: inhibition of CSPG accumulation:
Next, also in Example 4, the eyeball was extracted by the same method as in Example 1, and frozen blocks and sections were prepared. Sections were fixed with acetone (Sigma Aldrich Japan) for 10 minutes, washed with phosphate buffer, and anti-chondroitin sulfate proteoglycan (CSPG) antibody (clone CS56, mouse monoclonal antibody, 10 μg / mL; biochemistry as primary antibody) Kogyo Co., Ltd.) was added and reacted at room temperature for 1 hour. Subsequently, a secondary antibody reaction was performed using a histofine mouse stain kit (manufactured by Nichirei; used for mouse monoclonal antibody), and then DAB substrate (manufactured by Nichirei) was added to perform an enzyme dye reaction. This specimen was observed using an optical microscope (Leica). The results are shown in FIG. 5 (original drawing is color). Since CS56 recognizes CSPG in general, versican is also recognized. In the group not treated with type 2 diabetes model mice, CSPG increased / accumulated in the vitreous retina, whereas in the versican SiRNA-treated group, such CSPG increased / accumulated was almost completely suppressed. This result shows that not only gene expression but also enhanced expression at the glycoprotein level was suppressed almost completely by versican SiRNA gene silencing.

Example 6: Versican gene silencing effect in Streptozotocin-induced type 2 diabetic retinopathy model mouse: inhibition of vascular endothelial cell proliferation:
A section obtained by the same method as in Example 5 was fixed with acetone (manufactured by Sigma-Aldrich Japan) for 10 minutes, washed with a phosphate buffer, and rat-derived anti-vascular endothelial cell antibody (CD31; 1: 1: primary antibody). 200 dilution; manufactured by Pharmingen) was added and allowed to react at room temperature for 1 hour. Next, peroxidase-labeled donkey-derived anti-rat IgG (1: 200 dilution; manufactured by Biosource), which is a secondary antibody, was added and reacted at room temperature for 30 minutes. DAB substrate (Nichirei) was added to the sample after the reaction. This specimen was observed using an optical microscope (Leica).

  The obtained tissue image is shown in FIG. 6 (the original image is in color). In the untreated group, the number of CD31-positive cells on the retinal vitreous side increased, whereas in the SiRNA-treated group, the increase in CD31-positive cells at the same site was almost completely suppressed. From the above results, it was suggested that vascular endothelial growth of the vitreous side retina in a type 2 diabetes model is suppressed by versican gene silencing treatment.

Example 7: Versican gene silencing effect in Streptozotocin-induced type 2 diabetic retinopathy model mouse: inhibition of type IV collagen growth:
A section obtained by the same method as in Example 5 was fixed with acetone (manufactured by Sigma-Aldrich Japan) for 10 minutes, washed with a phosphate buffer, and a rabbit-derived anti-type IV collagen antibody (1: 250 dilution) as a primary antibody. And Sigma) were added and reacted at room temperature for 1 hour. Next, peroxidase-labeled anti-rabbit IgG (1: 200 dilution; manufactured by Jackson ImmunoResearch), which is a secondary antibody, was added and reacted at room temperature for 30 minutes. DAB substrate (Nichirei) was added to the sample after the reaction. This specimen was observed using an optical microscope (Leica).

  The obtained tissue image is shown in FIG. 7 (the original image is in color). In the untreated group, type IV collagen growth was observed in the vitreous retina, whereas in the SiRNA treated group, it was significantly suppressed. From the above results, it became clear that retinal collagen growth in type 2 diabetes model can be suppressed by versican gene silencing treatment.

Example 8: Versican gene silencing effect in hyperoxia-induced premature infant retinopathy model mice: suppression of vascular proliferation:
The clinical effect of versican siRNA gene silencing in hyperoxia-dependent retinopathy model mice (Shih SC et al. J. Clin. Invest. 112: 50-57, 2003), which is widely used as a model for retinopathy of prematurity Was added. C57BL / 6Jcl mice (manufactured by CLEA Japan, Inc.) on the 7th day after birth are raised for 5 days in a box maintained with high concentration of 75% ± 2% and returned to the normal room on the 12th day after birth. On the 17th to 21st days after birth, retinal neovascularization was induced by high-concentration oxygen. On day 12, the same versican siRNA cocktail (5′-ATGAAAGGCATCTTATGGATGTGCTCA-3 ′ (SEQ ID NO: 67); 5′-ATTACTAACCCATGCACTACATCAA-3 ′ (SEQ ID NO: 68); 5′-GGCAGCCACCAGCAGGTACACTCTG-3 ′ ( SEQ ID NO: 69); 5′-CTGCTCAACAGGCTTGTTTGGATAT-3 ′ (SEQ ID NO: 70), 1 μg / mouse, Gene World Inc., or PBS mixed with atelocollagen (Coken Inc.) diluted 10-fold with PBS in advance. 100 μl was injected intraperitoneally.

  On the 17th day after birth, both groups of mice were injected with a solution of Fluorscein-Dextran (manufactured by Sigma) in PBS from the left ventricle under general anesthesia, and the eyeballs were removed and fixed in 4% paraformaldehyde for 24 hours. Thereafter, the retina was taken out and used as an extended specimen, and angiographic imaging was performed with a fluorescent stereomicroscope (manufactured by Leica). The results are shown in FIG. 8 (original drawing is color). In the untreated group, neovascularization and increased vascular permeability were observed, whereas in the SiRNA treated group, it was remarkably suppressed. From the above results, it was found that retinal neovascularization can be suppressed by versican gene silencing treatment.

  As an example of examining the effect of accumulation of chondroitin sulfate proteoglycan (CSPG) according to the present invention, Versican siRNA containing the core site sequence of Versican, one of chondroitin sulfate proteoglycans, is chondroitin sulfate of the choroid. By suppressing the accumulation of proteoglycan and suppressing angiogenesis, it has an effect on the treatment or prevention of diabetic retinopathy and retinopathy of prematurity. The inhibitory agent for retina choroid angiogenesis according to the present invention suppresses Versican expression by administration of Versican siRNA and has an effect of suppressing the accumulation of chondroitin sulfate proteoglycan around the retina choroid. It is very useful for suppression. The method of treating or preventing diabetic retinopathy and retinopathy of prematurity by administering the retina choroidal neovascularization inhibitor having the accumulation inhibitory effect of chondroitin sulfate proteoglycan of the present invention is based on an unprecedented mechanism of action and drug therapy. Since the lesion can be effectively improved, it can be an excellent therapy useful for further improvement of the patient's QOL and medical care.

  All publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety.

It is a photograph which shows the attenuation effect of CSPG of chondroitin-4-desulfating enzyme in a type 2 diabetic retinopathy model mouse. The CSPG (CS56) dyeing | staining image (brown, arrow) in a type 2 diabetes model mouse retina is shown. It is a photograph which shows the blood vessel growth inhibitory effect of chondroitin-4-desulfating enzyme in a type 2 diabetic retinopathy model mouse. The vascular endothelial cell (CD31) dyeing | staining image (brown, arrow) in a type 2 diabetes model mouse retina is shown. It is a photograph which shows the collagen growth inhibition effect of chondroitin-4-desulfase in a type 2 diabetic retinopathy model mouse. A type IV collagen stained image (brown, arrow) in the type 2 diabetes model mouse retina is shown. It is a photograph which shows the expression silencing effect by versican expression enhancement in a type 2 diabetic retinopathy model mouse eyeball, and versican SiRNA treatment. The versican gene expression of the eyeball of a type 2 diabetes model mouse is shown. GAPDH is shown as an internal control. In the untreated group (left), enhanced versican expression is observed, whereas in the SiRNA treated group (right), versican expression is suppressed. It is a photograph which shows the suppression of CSPG accumulation by versican SiRNA treatment in type 2 diabetic retinopathy model mouse eyeball. The CSPG (CS56) dyeing | staining image (brown, arrow) in a type 2 diabetes model mouse retina is shown. It is a photograph which shows suppression of the vascular proliferation by versican SiRNA treatment in a type 2 diabetic retinopathy model mouse eyeball. The vascular endothelial cell (CD31) dyeing | staining image (brown, arrow) in a type 2 diabetes model mouse retina is shown. It is a photograph which shows suppression of the collagen growth by versican SiRNA treatment in a type 2 diabetic retinopathy model mouse eyeball. A type IV collagen stained image (brown, arrow) in the type 2 diabetes model mouse retina is shown. It is a photograph showing suppression of angiogenesis by versican SiRNA treatment in hyperoxia-dependent retinal neovascularization. A retinal extension specimen is shown. New blood vessels (green, arrows) are suppressed in the treatment group.

Claims (12)

  A retina choroidal neovascularization inhibitor comprising, as an active ingredient, a substance that inhibits the production or accumulation of chondroitin sulfate proteoglycans.   The drug according to claim 1, wherein the substance has a chondroitin sulfate proteoglycan degradation promoting action.   The drug according to claim 1, wherein the substance has a chondroitin sulfate proteoglycan synthesis inhibitory action.   The drug according to claim 1, wherein the substance has a chondroitin sulfate proteoglycan desulfation effect.   The drug according to claim 1, wherein the substance is a substance having a chondroitin sulfate proteoglycan sulfation inhibitory action.   The agent according to any one of claims 1 to 5, wherein production or accumulation of chondroitin sulfate proteoglycan is inhibited in the retina choroid.   The agent according to any one of claims 1 to 6, which is used for treatment or prevention of a choroidal neovascular disease.   The drug according to claim 7, wherein the retina choroidal neovascular disease is a retinal neovascular disease.   The drug according to claim 7, wherein the retina choroidal neovascular disease is diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, or age-related macular degeneration.   A screening method for a retina choroidal neovascularization inhibitor, comprising selecting a substance having an action of inhibiting the production or accumulation of chondroitin sulfate proteoglycan from a test sample. The screening method of Claim 10 including the process of selecting the substance which has the effect | action in any of the following (a)-(d).
(A) Degradation promoting action of chondroitin sulfate proteoglycan (b) Synthesis inhibition action of chondroitin sulfate proteoglycan (c) Desulfation action of chondroitin sulfate proteoglycan (d) Sulfation inhibition action of chondroitin sulfate proteoglycan   The screening method according to claim 10 or 11, wherein the inhibitor of retina choroidal neovascularization is for treatment or prevention of retina choroidal neovascularization disease.